Phenotypes related to Treatment of Ovarian Cancer ~ Ovarian Cancer — Risk / Phenotype

List was last updated on Nov 12, 2019 @ 4:18 am.


    • A TGF-β associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer.
    • Gagno S, Poletto E, Bartoletti M, Quartuccio L, Romualdi C, Garziera M, Scalone S, Sorio R, Dreussi E, Zanusso C, De Mattia E, Roncato R, Cecchin E, Giorda G, De Vita S, Dal Bo M, Puglisi F, Toffolia G.
    • Gynecol Oncol. 2019 Nov 8. pii: S0090-8258(19)31603-8. doi: 10.1016/j.ygyno.2019.10.019. [Epub ahead of print]
    • A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer.
    • Miller A, Bell-McGuinn KM, Schilder RJ, Walkera JL, O’Cearbhaill RE, Guntupalli SR, Armstrong DK, Hagemann AR, Gray HJ, Duska LR, Mathews CA, Chen A, O’Malley D, Gordon S, Fracasso PM, Aghajanian C.
    • Gynecol Oncol. 2019 Nov 7. pii: S0090-8258(19)31569-0. doi: 10.1016/j.ygyno.2019.10.012. [Epub ahead of print]
    • Bevacizumab As Maintenance Treatment in Patients With Ovarian Cancer: Wait for BRCA Testing.
    • Farolfi A, Lorusso D, Pignata S, De Giorgi U.
    • J Clin Oncol. 2019 Nov 7:JCO1902055. doi: 10.1200/JCO.19.02055. [Epub ahead of print]

    Original research:

    Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.

    • Molecular Profiles of BRCA1-Associated Ovarian Cancer Treated by Platinum-Based Therapy: Analysis of Primary, Residual and Relapsed Tumours.
    • Sokolenko AP, Bizin IV, Preobrazhenskaya EV, Gorodnova TV, Ivantsov AO, Iyevleva AG, Savonevich EL, Kotiv KB, Kuligina ES, Imyanitov EN.
    • Int J Cancer. 2019 Nov 6. doi: 10.1002/ijc.32776. [Epub ahead of print]
    • Study: Niraparib increases progression-free survival in patients with newly diagnosed ovarian cancer.
    • [No author given.]
    • FORCE. XRAYS. 2019 Nov 5.

    Original research:

    Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

    • Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome.
    • Cecere SC, Giannone G, Salutari V, Arenare L, Lorusso D, Ronzino G, Lauria R, Cormio G, Carella C, Scollo P, Ghizzoni V, Raspagliesi F, Di Napoli M, Mazzoni E, Marchetti C, Bergamini A, Orditura M, Valabrega G, Scambia G, Maltese G, De Matteis E, Cardalesi C, Loizzi V, Boccia S, Naglieri E, Scandurra G, Pignata S.
    • Gynecol Oncol. 2019 Nov 4. pii: S0090-8258(19)31607-5. doi: 10.1016/j.ygyno.2019.10.023. [Epub ahead of print]
    • Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives - a review.
    • Gupta S, Nag S, Aggarwal S, Rauthan A, Warrier N.
    • J Ovarian Res. 2019 Nov 4;12(1):103. doi: 10.1186/s13048-019-0579-0.
    • Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety.
    • Kristeleit RS, Oaknin A, Ray-Coquard I, Leary A, Balmaña J, Drew Y, Oza AM, Shapira-Frommer R, Domchek SM, Cameron T, Maloney L, Goble S, Lorusso D, Ledermann JA, McNeish IA.
    • Int J Gynecol Cancer. 2019 Nov;29(9):1396-1404. doi: 10.1136/ijgc-2019-000623.
    • Cox-LASSO Analysis Reveals a Ten-lncRNA Signature to Predict Outcomes in Patients with High-Grade Serous Ovarian Cancer.
    • Xu L, Wu Y, Che X, Zhao J, Wang F, Wang P, Qu X, Liu Y, Li Z.
    • DNA Cell Biol. 2019 Oct 29. doi: 10.1089/dna.2019.4826. [Epub ahead of print]
    • FDA Approval of Myriad Genetics CDx Adds HRD to Growing List of Ovarian Cancer Predictive Markers.
    • Ray T.
    • GenomeWeb. 2019 Oct 29.
    • Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach.
    • Boussios S, Karihtala P, Moschetta M, Abson C, Karathanasi A, Zakynthinakis-Kyriakou N, Ryan JE, Sheriff M, Rassy E, Pavlidis N.
    • Invest New Drugs. 2019 Oct 24. doi: 10.1007/s10637-019-00867-4. [Epub ahead of print]
    • Review
    • FDA Approves GSK's Zejula Alongside Myriad Genetics CDx for Advanced Ovarian Cancer.
    • [No author given]
    • GenomeWeb. 2019 Oct 23.
    • A 3-Tier Chemotherapy Response Score for Ovarian/Fallopian Tube/Peritoneal High-grade Serous Carcinoma: Is it Clinically Relevant?
    • Lawson BC, Euscher ED, Bassett RL, Liu J, Ramalingam P, Zhong Y, Fleming ND, Malpica A.
    • Am J Surg Pathol. 2019 Oct 22. doi: 10.1097/PAS.0000000000001391. [Epub ahead of print]
    • Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2).
    • Biessen DA, Brunetto AT, Arkenau HT, Tchakov I, Beijnen JH, De Grève J, Schellens JHM.
    • Invest New Drugs. 2019 Oct 21. doi: 10.1007/s10637-019-00857-6. [Epub ahead of print]
    • PARP Inhibition in Cancer: An Update on Clinical Development.
    • Sachdev E, Tabatabai R, Roy V, Rimel BJ, Mita MM.
    • Target Oncol. 2019 Oct 17. doi: 10.1007/s11523-019-00680-2. [Epub ahead of print]
    • Review
    • Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status.
    • Tomao F, Bardhi E, Di Pinto A, Sassu CM, Biagioli E, Petrella MC, Palaia I, Muzii L, Colombo N, Panici PB.
    • Cancer Treat Rev. 2019 Oct 9;80:101909. doi: 10.1016/j.ctrv.2019.101909. [Epub ahead of print]
    • Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance: Still getting any benefit? A case-control study.
    • Marchetti C, Rosati A, Scaletta G, Pietragalla A, Arcieri M, Ergasti R, Palluzzi E, Scambia G, Fagotti A.
    • Gynecol Oncol. 2019 Oct 9. pii: S0090-8258(19)31545-8. doi: 10.1016/j.ygyno.2019.09.020. [Epub ahead of print]
    • Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers.
    • Labidi-Galy SI, de La Motte Rouge T, Derbel O, Wolfer A, Kalbacher E, Olivier T, Combes JD, Heimgartner-Hu K, Tredan O, Guevara H, Heudel PE, Reverdy T, Bazan F, Heinzelmann-Schwarz V, Fehr M, de Castelbajac V, Vaflard P, Crivelli L, Bonadona V, Viassolo V, Buisson A, Golmard L, Rodrigues M, Ray-Coquard I.
    • Gynecol Oncol. 2019 Oct 8. pii: S0090-8258(19)31528-8. doi: 10.1016/j.ygyno.2019.09.008. [Epub ahead of print]
    • ADP-ribosylation Levels and Patterns Correlate with Gene Expression and Clinical Outcomes in Ovarian Cancers.
    • Conrad LB, Lin KY, Nandu T, Gibson BA, Lea JS, Kraus WL.
    • Mol Cancer Ther. 2019 Oct 8. pii: molcanther.0569.2019. doi: 10.1158/1535-7163.MCT-19-0569. [Epub ahead of print]
    • Success for First-Line PARP Inhibition in Ovarian Cancer.
    • [No authors listed]
    • Cancer Discov. 2019 Oct 7. doi: 10.1158/2159-8290.CD-NB2019-121. [Epub ahead of print]
    • News
    • PARP Inhibitors Center Stage for Ovarian Cancer — PRIMA, PAOLA-1, and VELIA Trials
    • Banerjee SN.
    • Medscape Oncology. 2019 Oct 7.
    • Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy.
    • Curtin NJ, Drew Y, Sharma-Saha S.
    • Nat Rev Clin Oncol. 2019 Oct 3. doi: 10.1038/s41571-019-0285-2. [Epub ahead of print]
    • Commentary
    • Genetic testing in ovarian cancer - clinical impact and current practices.
    • Knabben L, Imboden S, Mueller MD.
    • Horm Mol Biol Clin Investig. 2019 Oct 2. pii: /j/hmbci.ahead-of-print/hmbci-2019-0025/hmbci-2019-0025.xml. doi: 10.1515/hmbci-2019-0025. [Epub ahead of print]
    • Review
    • Aberrant Promoter Hypermethylation of RASSF1a and BRCA1 in Circulating Cell-Free Tumor DNA Serves as a Biomarker of Ovarian Carcinoma.
    • S SK, Swamy SN, Premalatha CS, Pallavi VR, Gawari R.
    • Asian Pac J Cancer Prev. 2019 Oct 1;20(10):3001-3005. doi: 10.31557/APJCP.2019.20.10.3001.
    • Prognostic significance of supraclavicular lymphadenopathy in patients with high-grade serous ovarian cancer.
    • Cybulska P, Hayes SA, Spirtos A, Rafizadeh MJ, Filippova OT, Leitao M, Zivanovic O, Sonoda Y, Mueller J, Lakhman Y, Long K, Chi DS.
    • Int J Gynecol Cancer. 2019 Oct 1. pii: ijgc-2019-000829. doi: 10.1136/ijgc-2019-000829. [Epub ahead of print]
    • Patients with BRCA mutated ovarian cancer may have fewer circulating MDSC and more peripheral CD8+ T cells compared with women with BRCA wild-type disease during the early disease course.
    • Lee JM, Botesteanu DA, Tomita Y, Yuno A, Lee MJ, Kohn EC, Annunziata CM, Matulonis U, MacDonald LA, Nair JR, Macneill KM, Trepel JB.
    • Oncol Lett. 2019 Oct;18(4):3914-3924. doi: 10.3892/ol.2019.10731. Epub 2019 Aug 7.
    • PARP Inhibitors Move Into First-Line for Ovarian Cancer.
    • Chustecka Z.
    • Medscape Oncology. 2019 Sep 29.

    Original research:

    Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

    Original research:

    Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.

    • Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.
    • Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Efrat Ben-Baruch N, Werner TL, Cloven NG, Oaknin A, DiSilvestro PA, Morgan MA, Nam JH, Leath CA 3rd, Nicum S, Hagemann AR, Littell RD, Cella D, Baron-Hay S, Garcia-Donas J, Mizuno M, Bell-McGuinn K, Sullivan DM, Bach BA, Bhattacharya S, Ratajczak CK, Ansell PJ, Dinh MH, Aghajanian C, Bookman MA.
    • N Engl J Med. 2019 Sep 28. doi: 10.1056/NEJMoa1909707. [Epub ahead of print]
    • Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
    • González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, Baumann K, Jardon K, Redondo A, Moore RG, Vulsteke C, O'Cearbhaill RE, Lund B, Backes F, Barretina-Ginesta P, Haggerty AF, Rubio-Pérez MJ, Shahin MS, Mangili G, Bradley WH, Bruchim I, Sun K, Malinowska IA, Li Y, Gupta D, Monk BJ; PRIMA/ENGOT-OV26/GOG-3012 Investigators.
    • N Engl J Med. 2019 Sep 28. doi: 10.1056/NEJMoa1910962. [Epub ahead of print]

    Research news: Study: Niraparib increases progression-free survival in patients with newly diagnosed ovarian cancer. (FORCE. XRAYS.)

    • Advances in the treatment of ovarian cancer using PARP inhibitors and the underlying mechanism of resistance.
    • Wang L, Wang Q, Xu Y, Han L.
    • Curr Drug Targets. 2019 Sep 25. doi: 10.2174/1389450120666190925123507. [Epub ahead of print]
    • Review
    • Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline BRCA mutations: OPINION Phase IIIb study design.
    • Poveda AM, Davidson R, Blakeley C, Milner A.
    • Future Oncol. 2019 Sep 25. doi: 10.2217/fon-2019-0343. [Epub ahead of print]
    • Can somatic BRCA2 status solve a case of olaparib monotherapy resistance?
    • Pietragalla A, Minucci A, Marchetti C, Scambia G, Fagotti A.
    • Int J Gynecol Cancer. 2019 Sep 19. pii: ijgc-2019-000757. doi: 10.1136/ijgc-2019-000757. [Epub ahead of print]
    • ALDH1A1 contributes to PARP inhibitor resistance via enhancing DNA repair in BRCA2-/- ovarian cancer cells.
    • Liu L, Cai S, Han C, Banerjee A, Wu D, Cui T, Xie G, Zhang J, Zhang X, McLaughlin E, Yin M, Backes FJ, Chakravarti A, Zheng Y, Wang QE.
    • Mol Cancer Ther. 2019 Sep 18. pii: molcanther.0242.2019. doi: 10.1158/1535-7163.MCT-19-0242. [Epub ahead of print]
    • Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial.
    • Matulonis UA, Walder L, Nøttrup TJ, Bessette P, Mahner S, Gil-Martin M, Kalbacher E, Ledermann JA, Wenham RM, Woie K, Lau S, Marmé F, Casado Herraez A, Hardy-Bessard AC, Banerjee S, Lindahl G, Benigno B, Buscema J, Travers K, Guy H, Mirza MR.
    • J Clin Oncol. 2019 Sep 16:JCO1900917. doi: 10.1200/JCO.19.00917. [Epub ahead of print]
    • Olaparib in the treatment of ovarian cancer.
    • Washington CR, Richardson DL, Moore KN.
    • Future Oncol. 2019 Sep 3. doi: 10.2217/fon-2019-0271. [Epub ahead of print]
    • Review
    • [Synthetic Lethality - Its Current Application and Potential in Oncological Treatment.]
    • Bortlíková L, Müller P, Vojtěšek B, Rak V, Svoboda M.
    • Klin Onkol. 2019 Fall;32(Supplementum 3):19-24. doi: 10.14735/amko20193S.
    • Niraparib as maintenance therapy in a patient with ovarian cancer and brain metastases.
    • Gray S, Khor XY, Yiannakis D.
    • BMJ Case Rep. 2019 Aug 28;12(8). pii: e230738. doi: 10.1136/bcr-2019-230738.
    • Case report
    • Hopes and failures in front-line ovarian cancer therapy.
    • Tsibulak I, Zeimet AG, Marth C.
    • Crit Rev Oncol Hematol. 2019 Aug 14;143:14-19. doi: 10.1016/j.critrevonc.2019.08.002. [Epub ahead of print]
    • BRCA mutation frequency and clinical features of ovarian cancer patients: A report from a Chinese study group.
    • Bu H, Chen J, Li Q, Hou J, Wei Y, Yang X, Ma Y, He H, Zhang Y, Kong B.
    • J Obstet Gynaecol Res. 2019 Aug 14. doi: 10.1111/jog.14090. [Epub ahead of print]
    • Patterns and duration of primary and recurrent treatment in ovarian cancer patients with germline BRCA mutations.
    • Jorge S, Swisher EM, Norquist BM, Pennington KP, Gray HJ, Urban RR, Garcia RL, Doll KM.
    • Gynecol Oncol Rep. 2019 Aug 9;29:113-117. doi: 10.1016/j.gore.2019.08.001. eCollection 2019 Aug.
    • Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers.
    • Przybycinski J, Nalewajska M, Marchelek-Mysliwiec M, Dziedziejko V, Pawlik A.
    • Expert Opin Ther Targets. 2019 Aug 8. doi: 10.1080/14728222.2019.1654458. [Epub ahead of print]
    • Review
    • A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24.
    • Mirza MR, Bergmann TK, Mau-Sørensen M, Christensen RD, Åvall-Lundqvist E, Birrer MJ, Jørgensen M, Roed H, Malander S, Nielsen F, Lassen U, Brøsen K, Bjørge L, Mäenpää J.
    • Cancer Chemother Pharmacol. 2019 Aug 2. doi: 10.1007/s00280-019-03917-z. [Epub ahead of print]
    • The implications of genetic testing on radiotherapy decisions: a guide for radiation oncologists.
    • Bergom C, West CM, Higginson DS, Abazeed ME, Arun B, Bentzen SM, Bernstein JL, Evans JD, Gerber NK, Kerns SL, Keen J, Litton JK, Reiner AS, Riaz N, Rosenstein BS, Sawakuchi GO, Shaitelman SF, Powell SN, Woodward WA.
    • Int J Radiat Oncol Biol Phys. 2019 Aug 2. pii: S0360-3016(19)33530-8. doi: 10.1016/j.ijrobp.2019.07.026. [Epub ahead of print]
    • Review
    • Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review.
    • Boussios S, Karihtala P, Moschetta M, Karathanasi A, Sadauskaite A, Rassy E, Pavlidis N.
    • Diagnostics (Basel). 2019 Aug 1;9(3). pii: E87. doi: 10.3390/diagnostics9030087.
    • Chromosomal radiosensitivity of triple negative breast cancer patients.
    • Francies FZ, Herd O, Cairns A, Nietz S, Murdoch M, Slabbert J, Claes KB, Vral A, Baeyens A.
    • Int J Radiat Biol. 2019 Jul 26:1-30. doi: 10.1080/09553002.2019.1649502. [Epub ahead of print]
    • Chemotherapy Toxicity in BRCA Mutation Carriers Undergoing First-Line Platinum-Based Chemotherapy.
    • Weitzner O, Yagur Y, Kadan Y, Beiner ME, Fishman A, Ben Ezry E, Amitai Komem D, Helpman L.
    • Oncologist. 2019 Jul 25. pii: theoncologist.2019-0272. doi: 10.1634/theoncologist.2019-0272. [Epub ahead of print]
    • GSK Drug Helps Ovarian Cancer Patients Live Longer in Late-Stage Study.
    • Zainab Hussain N, Aripaka P.
    • Medscape Oncology. 2019 Jul 18.
    • Current role of poly(ADP-ribose) polymerase inhibitors: which poly(ADP-ribose) polymerase inhibitor and when?
    • Vanacker H, Romeo C, Ray-Coquard I.
    • Curr Opin Oncol. 2019 Jul 10. doi: 10.1097/CCO.0000000000000557. [Epub ahead of print]
    • Review
    • Tumour lineage shapes BRCA-mediated phenotypes.
    • Jonsson P, Bandlamudi C, Cheng ML, Srinivasan P, Chavan SS, Friedman ND, Rosen EY, Richards AL, Bouvier N, Selcuklu SD, Bielski CM, Abida W, Mandelker D, Birsoy O, Zhang L, Zehir A, Donoghue MTA, Baselga J, Offit K, Scher HI, O'Reilly EM, Stadler ZK, Schultz N, Socci ND, Viale A, Ladanyi M, Robson ME, Hyman DM, Berger MF, Solit DB, Taylor BS.
    • Nature. 2019 Jul 10. doi: 10.1038/s41586-019-1382-1. [Epub ahead of print]
    • Frequency of germline mutations in BRCA1 and BRCA2 in ovarian cancer patients and their effect on treatment outcome.
    • Ashour M, Ezzat Shafik H.
    • Cancer Manag Res. 2019 Jul 8;11:6275-6284. doi: 10.2147/CMAR.S206817. eCollection 2019.
    • Ovarian cancer risk factors by tumor aggressiveness: An analysis from the Ovarian Cancer Cohort Consortium.
    • Fortner RT, Poole EM, Wentzensen NA, Trabert B, White E, Arslan AA, Patel AV, Setiawan VW, Visvanathan K, Weiderpass E, Adami HO, Black A, Bernstein L, Brinton LA, Buring J, Clendenen TV, Fournier A, Fraser G, Gapstur SM, Gaudet MM, Giles GG, Gram IT, Hartge P, Hoffman-Bolton J, Idahl A, Kaaks R, Kirsh VA, Knutsen S, Koh WP, Lacey JV Jr, Lee IM, Lundin E, Merritt MA, Milne RL, Onland-Moret NC, Peters U, Poynter JN, Rinaldi S, Robien K, Rohan T, Sánchez MJ, Schairer C, Schouten LJ, Tjonneland A, Townsend MK, Travis RC, Trichopoulou A, van den Brandt PA, Vineis P, Wilkens L, Wolk A, Yang HP, Zeleniuch-Jacquotte A, Tworoger SS.
    • Int J Cancer. 2019 Jul 1;145(1):58-69. doi: 10.1002/ijc.32075. Epub 2019 Jan 14.
    • The clinical features associated with mutated BRCA1 and 2 genes in ovarian cancer patients.
    • Kubelac P, Vlad C, Berindan Neagoe I, Irimie A, Achimas Cadariu P.
    • J BUON. 2019 Jul-Aug;24(4):1538-1543.
    • The 34th Annual Meeting of the Korean Society of Gynecologic Oncology 2019: meeting report.
    • Yim GW, Suh DH, Kim JW, Kim SC, Kim YT.
    • J Gynecol Oncol. 2019 Jul;30(4):e91. doi: 10.3802/jgo.2019.30.e91.
    • Fallopian Tube Carcinoma.
    • Stasenko M, Fillipova O, Tew WP.
    • J Oncol Pract. 2019 Jul;15(7):375-382. doi: 10.1200/JOP.18.00662. Epub 2019 Jul 8.

    Commentary:

    Rapidly Changing Landscape of Fallopian Tube Carcinoma.

    • BRCA germline mutation test for all woman with ovarian cancer?
    • Paradiso AV, Digennaro M, Patruno M, De Summa S, Tommasi S, Berindan-Neagoe I.
    • BMC Cancer. 2019 Jun 28;19(1):641. doi: 10.1186/s12885-019-5829-4.
    • Europe OKs PARP Inhibitor Talazoparib in BRCA+ Breast Cancer.
    • Mulcahy N.
    • Medscape. Medscape Oncology. 2019 Jun 21.
    • Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.
    • Tewari KS, Burger RA, Enserro D, Norquist BM, Swisher EM, Brady MF, Bookman MA, Fleming GF, Huang H, Homesley HD, Fowler JM, Greer BE, Boente M, Liang SX, Ye C, Bais C, Randall LM, Chan JK, Ferriss JS, Coleman RL, Aghajanian C, Herzog TJ, DiSaia PJ, Copeland LJ, Mannel RS, Birrer MJ, Monk BJ.
    • J Clin Oncol. 2019 Jun 19:JCO1901009. doi: 10.1200/JCO.19.01009. [Epub ahead of print]

    Letter, Commentary:

    Bevacizumab As Maintenance Treatment in Patients With Ovarian Cancer: Wait for BRCA Testing.

    • Prognostic factors value of germline and somatic brca in patients undergoing surgery for recurrent ovarian cancer with liver metastases.
    • Gallotta V, Conte C, D'Indinosante M, Capoluongo E, Minucci A, De Rose AM, Ardito F, Giuliante F, Di Giorgio A, Zannoni GF, Fagotti A, Margreiter C, Scambia G, Ferrandina G.
    • Eur J Surg Oncol. 2019 Jun 13. pii: S0748-7983(19)30517-7. doi: 10.1016/j.ejso.2019.06.023. [Epub ahead of print]
    • Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.
    • Konstantinopoulos PA, Waggoner S, Vidal GA, Mita M, Moroney JW, Holloway R, Van Le L, Sachdev JC, Chapman-Davis E, Colon-Otero G, Penson RT, Matulonis UA, Kim YB, Moore KN, Swisher EM, Färkkilä A, D'Andrea A, Stringer-Reasor E, Wang J, Buerstatte N, Arora S, Graham JR, Bobilev D, Dezube BJ, Munster P.
    • JAMA Oncol. 2019 Jun 13. doi: 10.1001/jamaoncol.2019.1048. [Epub ahead of print]

    Editorial:

    Immune Checkpoint and Poly(ADP–Ribose) Polymerase Inhibition for Recurrent Platinum-Resistant Ovarian and Metastatic Triple-Negative Breast Cancers.

    Press: Niraparib-Pembrolizumab Combo May Have Benefit in Ovarian, Breast Cancers. (Medscape)

    • Clinical Impact of RANK Signalling in Ovarian Cancer.
    • Wieser V, Sprung S, Tsibulak I, Haybaeck J, Hackl H, Fiegl H, Marth C, Zeimet AG.
    • Cancers (Basel). 2019 Jun 8;11(6). pii: E791. doi: 10.3390/cancers11060791.
    • Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial.
    • Del Campo JM, Matulonis UA, Malander S, Provencher D, Mahner S, Follana P, Waters J, Berek JS, Woie K, Oza AM, Canzler U, Gil-Martin M, Lesoin A, Monk BJ, Lund B, Gilbert L, Wenham RM, Benigno B, Arora S, Hazard SJ, Mirza MR.
    • J Clin Oncol. 2019 Jun 7:JCO1802238. doi: 10.1200/JCO.18.02238. [Epub ahead of print]
    • Association between CT-texture-derived tumor heterogeneity, outcomes, and BRCA mutation status in patients with high-grade serous ovarian cancer.
    • Meier A, Veeraraghavan H, Nougaret S, Lakhman Y, Sosa R, Soslow RA, Sutton EJ, Hricak H, Sala E, Vargas HA.
    • Abdom Radiol (NY). 2019 Jun;44(6):2040-2047. doi: 10.1007/s00261-018-1840-5.
    • PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review.
    • Cook SA, Tinker AV.
    • BioDrugs. 2019 Jun;33(3):255-273. doi: 10.1007/s40259-019-00347-4.
    • Review
    • Efficacy and Safety Exposure-Response Analyses of Olaparib Capsule and Tablet Formulations in Oncology Patients.
    • Zhou D, Li J, Learoyd M, Bui K, Berges A, Milenkova T, Al-Huniti N, Tomkinson H, Xu H.
    • Clin Pharmacol Ther. 2019 Jun;105(6):1492-1500. doi: 10.1002/cpt.1338. Epub 2019 Feb 22.
    • Review
    • Increased risk of brain metastases in ovarian cancer patients with BRCA mutations.
    • Ratner E, Bala M, Louie-Gao M, Aydin E, Hazard S, Brastianos PK.
    • Gynecol Oncol. 2019 Jun;153(3):568-573. doi: 10.1016/j.ygyno.2019.03.004. Epub 2019 Mar 12.
    • Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives.
    • Gori S, Barberis M, Bella MA, Buttitta F, Capoluongo E, Carrera P, Colombo N, Cortesi L, Genuardi M, Gion M, Guarneri V, Incorvaia L, La Verde N, Lorusso D, Marchetti A, Marchetti P, Normanno N, Pasini B, Pensabene M, Pignata S, Radice P, Ricevuto E, Sapino A, Tagliaferri P, Tassone P, Trevisiol C, Truini M, Varesco L, Russo A; AIOM-SIGU-SIBIOC-SIAPEC-IAP Working Group.
    • Crit Rev Oncol Hematol. 2019 May 25;140:67-72. doi: 10.1016/j.critrevonc.2019.05.012. [Epub ahead of print]
    • Development of Peritoneal Carcinoma in women diagnosed with Serous Tubal Intraepithelial Carcinoma (STIC) following Risk-Reducing Salpingo-Oophorectomy (RRSO).
    • Stanciu PI, Ind TEJ, Barton DPJ, Butler JB, Vroobel KM, Attygalle AD, Nobbenhuis MAE.
    • J Ovarian Res. 2019 May 25;12(1):50. doi: 10.1186/s13048-019-0525-1.
    • Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer.
    • Ledermann JA, Pujade-Lauraine E.
    • Ther Adv Med Oncol. 2019 May 22;11:1758835919849753. doi: 10.1177/1758835919849753. eCollection 2019.
    • Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data.
    • Cohen PA, Powell A, Böhm S, Gilks CB, Stewart CJR, Meniawy TM, Bulsara M, Avril S, Brockbank EC, Bosse T, de Azevedo Focchi GR, Ganesan R, Glasspool RM, Howitt BE, Kim HS, Lee JY, Le ND, Lockley M, Manchanda R, Mandalia T, McCluggage WG, McNeish I, Midha D, Srinivasan R, Tan YY, van der Griend R, Yunokawa M, Zannoni GF; HGSC CR Collaborative Network (Supplementary 1), Singh N.
    • Gynecol Oncol. 2019 May 19. pii: S0090-8258(19)31181-3. doi: 10.1016/j.ygyno.2019.04.679. [Epub ahead of print]
    • PARP Inhibitors in Ovarian Cancer: The Route to "Ithaca".
    • Boussios S, Karathanasi A, Cooke D, Neille C, Sadauskaite A, Moschetta M, Zakynthinakis-Kyriakou N, Pavlidis N.
    • Diagnostics (Basel). 2019 May 18;9(2). pii: E55. doi: 10.3390/diagnostics9020055.
    • Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation status.
    • Stasenko M, Cybulska P, Feit N, Makker V, Konner J, O'Cearbhaill RE, Alektiar KM, Beal K, Gardner GJ, Long Roche KC, Sonoda Y, Chi DS, Zivanovic O, Leitao MM Jr, Cadoo KA, Tew WP.
    • Gynecol Oncol. 2019 May 18. pii: S0090-8258(19)31229-6. doi: 10.1016/j.ygyno.2019.05.004. [Epub ahead of print]
    • Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer.
    • Jiang X, Li W, Li X, Bai H, Zhang Z.
    • Cancer Manag Res. 2019 May 10;11:4371-4390. doi: 10.2147/CMAR.S200524. eCollection 2019.
    • Veliparib: a new therapeutic option in ovarian cancer?
    • Ghisoni E, Giannone G, Tuninetti V, Genta S, Scotto G, Aglietta M, Sangiolo D, Mittica G, Valabrega G.
    • Future Oncol. 2019 May 10. doi: 10.2217/fon-2018-0883. [Epub ahead of print]
    • Review
    • Is BRCA mutational status a predictor of platinum-based chemotherapy related hematologic toxicity in high-grade serous ovarian cancer patients?
    • Tomao F, Musacchio L, Di Mauro F, Boccia SM, Di Donato V, Giancotti A, Perniola G, Palaia I, Muzii L, Benedetti Panici P.
    • Gynecol Oncol. 2019 May 9. pii: S0090-8258(19)30504-9. doi: 10.1016/j.ygyno.2019.04.009. [Epub ahead of print]
    • FANCM, RAD1, CHEK1 and TP53I3 act as BRCA-like tumor suppressors and are mutated in hereditary ovarian cancer.
    • Lopes JL, Chaudhry S, Lopes GS, Levin NK, Tainsky MA.
    • Cancer Genet. 2019 May 8. pii: S2210-7762(19)30037-7. doi: 10.1016/j.cancergen.2019.04.061. [Epub ahead of print]
    • Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer.
    • Kim SI, Lee M, Kim HS, Chung HH, Kim JW, Park NH, Song YS.
    • J Ovarian Res. 2019 May 7;12(1):40. doi: 10.1186/s13048-019-0511-7.
    • Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes.
    • da Costa AABA, do Canto LM, Larsen SJ, Ribeiro ARG, Stecca CE, Petersen AH, Aagaard MM, de Brot L, Baumbach J, Baiocchi G, Achatz MI, Rogatto SR.
    • BMC Cancer. 2019 May 6;19(1):422. doi: 10.1186/s12885-019-5622-4.
    • Clinical and molecular characterization of ovarian carcinoma displaying isolated lymph node relapse.
    • Hollis RL, Carmichael J, Meynert AM, Churchman M, Hallas-Potts A, Rye T, Mackean M, Nussey F, Semple CA, Herrington CS, Gourley C.
    • Am J Obstet Gynecol. 2019 May 2. pii: S0002-9378(19)30620-9. doi: 10.1016/j.ajog.2019.04.035. [Epub ahead of print]
    • Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinoma.
    • Morse CB, Toukatly MN, Kilgore MR, Agnew KJ, Bernards SS, Norquist BM, Pennington KP, Garcia RL, Liao JB, Swisher EM.
    • Gynecol Oncol. 2019 May;153(2):217-222. doi: 10.1016/j.ygyno.2019.02.011. Epub 2019 Feb 23.

    Editorial:

    Do increased tumor infiltrating lymphocytes co-existing with Homologous Recombination Deficiency provide clues to enhance immunotherapy of ovarian cancer?

    • Fifteen-year survival of invasive epithelial ovarian cancer in women with BRCA1/2 mutations - the National Israeli Study of Ovarian Cancer.
    • Lavie O, Chetrit A, Novikov I, Sadetzki S; National Israeli Study of Ovarian Cancer.
    • Gynecol Oncol. 2019 May;153(2):320-325. doi: 10.1016/j.ygyno.2019.02.022. Epub 2019 Mar 11.
    • BRCA1-associated and sporadic ovarian carcinomas: outcomes of primary cytoreductive surgery or neoadjuvant chemotherapy.
    • Gorodnova T, Sokolenko A, Ni V, Ivantsov A, Kotiv K, Petrik S, Amelina I, Berlev I, Imyanitov E.
    • Int J Gynecol Cancer. 2019 May;29(4):779-786. doi: 10.1136/ijgc-2018-000175. Epub 2019 Mar 5.
    • Prevalence of germline pathogenic BRCA1/2 variants in sequential epithelial ovarian cancer cases.
    • Morgan RD, Burghel GJ, Flaum N, Bulman M, Clamp AR, Hasan J, Mitchell CL, Schlecht H, Woodward ER, Lallo FI, Crosbie EJ, Edmondson RJ, Wallace AJ, Jayson GC, Evans DGR.
    • J Med Genet. 2019 May;56(5):301-307. doi: 10.1136/jmedgenet-2018-105792. Epub 2019 Jan 25.
    • Olaparib maintenance for first-line treatment of ovarian cancer: will SOLO1 reset the standard of care?
    • Miller RE, Crusz SM, Ledermann JA.
    • Future Oncol. 2019 Apr 30. doi: 10.2217/fon-2019-0057. [Epub ahead of print]
    • Review
    • AB0 Blood Group and Ovarian Cancer Survival.
    • Mandato VD, Torricelli F, Mastrofilippo V, Ciarlini G, Pirillo D, Annunziata G, Casali B, Abrate M, Sala GB, Aguzzoli L.
    • J Cancer. 2019 Apr 25;10(9):1949-1957. doi: 10.7150/jca.29272. eCollection 2019.
    • Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk.
    • Lampert EJ, Hays JL, Kohn EC, Annunziata CM, Minasian L, Yu M, Gordon N, Sissung TM, Chiou VL, Figg WD, Houston N, Lee JM.
    • Oncotarget. 2019 Apr 23;10(30):2855-2868. doi: 10.18632/oncotarget.26869. eCollection 2019 Apr 23.
    • Efficacy and safety of olaparib maintenance therapy in platinum-sensitive ovarian cancer patients with BRCA mutations: a meta-analysis on randomized controlled trials.
    • Ma J, Deng H, Li J, Hu S, Yang Y, Liu S, Han X.
    • Cancer Manag Res. 2019 Apr 16;11:3061-3078. doi: 10.2147/CMAR.S191107. eCollection 2019.
    • Rucaparib in the landscape of PARP inhibition in ovarian cancer.
    • Colomba E, Pautier P, Pommeret F, Leary A.
    • Expert Rev Anticancer Ther. 2019 Apr 12. doi: 10.1080/14737140.2019.1607302. [Epub ahead of print]
    • Review
    • Comprehensive analysis of serum tumor markers and BRCA1/2 germline mutations in Chinese ovarian cancer patients.
    • Deng H, Chen M, Guo X, Heng J, Xu X, Peng L, Jiang H, Li G, Day JX, Li J, Shan D, Li Y, Zhou Y, Liu B, Dai L, Wang X, Wang J.
    • Mol Genet Genomic Med. 2019 Apr 10:e672. doi: 10.1002/mgg3.672. [Epub ahead of print]
    • Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer.
    • Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel BJ, Buss MK, Nattam SR, Hurteau J, Luo W, Curtis J, Whalen C, Kohn EC, Ivy SP, Matulonis UA.
    • Ann Oncol. 2019 Apr 1;30(4):551-557. doi: 10.1093/annonc/mdz018.
    • Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
    • Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza AM, Cristea M, Berek JS, Chan JK, Rimel BJ, Matei DE, Li Y, Sun K, Luptakova K, Matulonis UA, Monk BJ.
    • Lancet Oncol. 2019 Apr 1. pii: S1470-2045(19)30029-4. doi: 10.1016/S1470-2045(19)30029-4. [Epub ahead of print]

    Commentary:

    Fighting against the challenge of treating patients with late-line ovarian cancer: are we there yet?

    • 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.
    • Hurley RM, Wahner Hendrickson AE, Visscher DW, Ansell P, Harrell MI, Wagner JM, Negron V, Goergen KM, Maurer MJ, Oberg AL, Meng XW, Flatten KS, De Jonge MJA, Van Herpen CD, Gietema JA, Koornstra RHT, Jager A, den Hollander MW, Dudley M, Shepherd SP, Swisher EM, Kaufmann SH.
    • Gynecol Oncol. 2019 Apr;153(1):127-134. doi: 10.1016/j.ygyno.2019.01.015. Epub 2019 Jan 25.
    • Rucaparib: A Poly(ADP-Ribose) Polymerase Inhibitor for BRCA-Mutated Relapsed Ovarian Cancer.
    • Moore DC, Ringley JT, Patel J.
    • J Pharm Pract. 2019 Apr;32(2):219-224. doi: 10.1177/0897190017743131. Epub 2017 Nov 22.
    • Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.
    • Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Cadoo KA, Shapiro GI, Mayer EL, O'Cearbhaill RE, Coleman RL, Kochupurakkal B, Whalen C, Curtis J, Farooq S, Luo W, Eismann J, Buss MK, Aghajanian C, Mills GB, Palakurthi S, Kirschmeier P, Liu J, Cantley LC, Kaufmann SH, Swisher EM, D'Andrea AD, Winer E, Wulf GM, Matulonis UA.
    • Lancet Oncol. 2019 Apr;20(4):570-580. doi: 10.1016/S1470-2045(18)30905-7. Epub 2019 Mar 14.

    Commentary:

    Extending the scope of PARP inhibitors in ovarian cancer.

    • Rucaparib: A Review in Ovarian Cancer.
    • Shirley M.
    • Target Oncol. 2019 Apr;14(2):237-246. doi: 10.1007/s11523-019-00629-5.
    • Review
    • PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers.
    • Keung MYT, Wu Y, Vadgama JV.
    • J Clin Med. 2019 Mar 30;8(4). pii: E435. doi: 10.3390/jcm8040435.
    • Advances in the use of PARP inhibitors for BRCA1/2-associated breast cancer: talazoparib.
    • McCann KE.
    • Future Oncol. 2019 Mar 26. doi: 10.2217/fon-2018-0751. [Epub ahead of print]
    • Review
    • Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations.
    • Madariaga A, Lheureux S, Oza AM.
    • Cancers (Basel). 2019 Mar 23;11(3). pii: E416. doi: 10.3390/cancers11030416.
    • TWiST Strengthens PARP Inhibitor Role in Ovarian Cancer.
    • Harrison P.
    • Medscape Oncology. Conference News. 2019 Mar 18.
    • Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer.
    • Shao N, Shi Y, Yu L, Ye R, Shan Z, Zhang Z, Zhang Y, Lin Y.
    • Int J Biol Sci. 2019 Mar 10;15(5):962-972. doi: 10.7150/ijbs.30721. eCollection 2019.
    • Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer.
    • Foote JR, Secord AA, Liang MI, Ehrisman JA, Cohn DE, Jewell E, Havrilesky LJ.
    • Gynecol Oncol. 2019 Mar;152(3):445-451. doi: 10.1016/j.ygyno.2018.11.028.
    • Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial.
    • Fabbro M, Moore KN, Dørum A, Tinker AV, Mahner S, Bover I, Banerjee S, Tognon G, Goffin F, Shapira-Frommer R, Wenham RM, Hellman K, Provencher D, Harter P, Vázquez IP, Follana P, Pineda MJ, Mirza MR, Hazard SJ, Matulonis UA.
    • Gynecol Oncol. 2019 Mar;152(3):560-567. doi: 10.1016/j.ygyno.2018.12.009. Epub 2019 Jan 9.
    • Major clinical research advances in gynecologic cancer in 2018.
    • Kim M, Suh DH, Lee KH, Eom KY, Toftdahl NG, Mirza MR, Kim JW.
    • J Gynecol Oncol. 2019 Mar;30(2):e18. doi: 10.3802/jgo.2019.30.e18.
    • Combined Targeted Resequencing of Cytosine DNA Methylation and Mutations of DNA Repair Genes with Potential Use for Poly(ADP-Ribose) Polymerase 1 Inhibitor Sensitivity Testing.
    • Grimm C, Fischer A, Farrelly AM, Kalachand R, Castiglione R, Wasserburger E, Hussong M, Schultheis AM, Altmüller J, Thiele H, Reinhardt HC, Hauschulz K, Hennessy BT, Herwig R, Lienhard M, Buettner R, Schweiger MR.
    • J Mol Diagn. 2019 Mar;21(2):198-213. doi: 10.1016/j.jmoldx.2018.10.007. Epub 2018 Dec 19.
    • Durable response by olaparib for a Japanese patient with primary peritoneal cancer with multiple brain metastases: A case report.
    • Sakamoto I, Hirotsu Y, Nakagomi H, Ikegami A, Teramoto K, Omata M.
    • J Obstet Gynaecol Res. 2019 Mar;45(3):743-747. doi: 10.1111/jog.13851. Epub 2018 Nov 22.
    • Case report
    • High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints.
    • Lisio MA, Fu L, Goyeneche A, Gao ZH, Telleria C.
    • Int J Mol Sci. 2019 Feb 22;20(4). pii: E952. doi: 10.3390/ijms20040952.
    • Exaggeration of PFS by blinded, independent, central review (BICR).
    • Stone A, Gebski V, Davidson R, Bloomfield R, Bartlett JW, Sabin A.
    • Ann Oncol. 2019 Feb 1;30(2):332-338. doi: 10.1093/annonc/mdy514.
    • Radiosensitivity Is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors.
    • Barazas M, Gasparini A, Huang Y, Küçükosmanoğlu A, Annunziato S, Bouwman P, Sol W, Kersbergen A, Proost N, de Korte-Grimmerink R, van de Ven M, Jonkers J, Borst GR, Rottenberg S.
    • Cancer Res. 2019 Feb 1;79(3):452-460. doi: 10.1158/0008-5472.CAN-18-2077. Epub 2018 Dec 10.
    • Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer.
    • Lee CK, Scott C, Lindeman GJ, Hamilton A, Lieschke E, Gibbs E, Asher R, Badger H, Paterson R, Macnab L, Kwan EM, Francis PA, Boyle F, Friedlander M.
    • Br J Cancer. 2019 Feb;120(3):279-285. doi: 10.1038/s41416-018-0349-6. Epub 2019 Jan 17.
    • BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
    • Lin KK, Harrell MI, Oza AM, Oaknin A, Ray-Coquard I, Tinker AV, Helman E, Radke MR, Say C, Vo LT, Mann E, Isaacson JD, Maloney L, O'Malley DM, Chambers SK, Kaufmann SH, Scott CL, Konecny GE, Coleman RL, Sun JX, Giordano H, Brenton JD, Harding TC, McNeish IA, Swisher EM.
    • Cancer Discov. 2019 Feb;9(2):210-219. doi: 10.1158/2159-8290.CD-18-0715. Epub 2018 Nov 13.
    • Update in the use and evaluation of poly (ADP-ribose) polymerase inhibitors in epithelial ovarian cancer: current and pending clinical research.
    • Washington C, Gunderson CC, Moore KN.
    • Curr Opin Obstet Gynecol. 2019 Feb;31(1):4-11. doi: 10.1097/GCO.0000000000000507.
    • Review
    • Poly-ADP-ribosyl-polymerase inhibitor resistance mechanisms and their therapeutic implications.
    • McCann KE.
    • Curr Opin Obstet Gynecol. 2019 Feb;31(1):12-17. doi: 10.1097/GCO.0000000000000517.
    • Review
    • The road to long-term survival: Surgical approach and longitudinal treatments of long-term survivors of advanced-stage serous ovarian cancer.
    • Javellana M, Hoppenot C, Lengyel E.
    • Gynecol Oncol. 2019 Feb;152(2):228-234. doi: 10.1016/j.ygyno.2018.11.007. Epub 2018 Nov 22.
    • Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients.
    • Rodriguez-Freixinos V, Fariñas-Madrid L, Gil-Martin M, Barretina-Ginesta P, Romeo M, Villacampa G, Pardo B, Ahmed H, Recalde S, Piulats JM, Gómez-Plaza MC, Gil-Moreno A, Sala E, Martínez-Román S, Ponce J, Meléndez C, Carballas E, Dientsmann R, Oaknin A.
    • Gynecol Oncol. 2019 Feb;152(2):270-277. doi: 10.1016/j.ygyno.2018.11.036. Epub 2018 Dec 12.
    • Pathogenic BRCA1 mutations may be necessary but not sufficient for tissue genomic heterogeneity: Deep sequencing data from ovarian cancer patients.
    • Kotoula V, Lakis S, Tikas I, Giannoulatou E, Lazaridis G, Papadopoulou K, Manoussou K, Efstratiou I, Papanikolaou A, Fostira F, Vlachos I, Tarlatzis B, Fountzilas G.
    • Gynecol Oncol. 2019 Feb;152(2):375-386. doi: 10.1016/j.ygyno.2018.11.016. Epub 2018 Nov 14.
    • Olaparib: A tale of two dosage forms.
    • Christ TN.
    • Semin Oncol. 2019 Feb;46(1):100-101. doi: 10.1053/j.seminoncol.2018.11.003. Epub 2018 Dec 19.
    • Phase Ib with expansion study of olaparib plus weekly (Metronomic) carboplatin and paclitaxel in relapsed ovarian cancer patients.
    • Rivkin SE, Moon J, Iriarte DS, Bailey E, Sloan HL, Goodman GE, BonDurant AE, Velijovich D, Wahl T, Jiang P, Shah CA, Drescher C, Fer MF, Kaplan HG, Ellis ED.
    • Int J Gynecol Cancer. 2019 Jan 29. pii: ijgc-2018-000035. doi: 10.1136/ijgc-2018-000035. [Epub ahead of print]
    • Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
    • Gadducci A, Guarneri V, Peccatori FA, Ronzino G, Scandurra G, Zamagni C, Zola P, Salutari V.
    • J Ovarian Res. 2019 Jan 28;12(1):9. doi: 10.1186/s13048-019-0484-6.
    • Glucocorticoid receptor expression is associated with inferior overall survival independent of BRCA mutation status in ovarian cancer.
    • Veneris JT, Huang L, Churpek JE, Conzen SD, Fleming GF.
    • Int J Gynecol Cancer. 2019 Jan 25. pii: ijgc-2018-000101. doi: 10.1136/ijgc-2018-000101. [Epub ahead of print]
    • Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas.
    • Yi T, Feng Y, Sundaram R, Tie Y, Zheng H, Qian Y, You D, Yi T, Wang P, Zhao X.
    • Int J Cancer. 2019 Jan 21. doi: 10.1002/ijc.32143. [Epub ahead of print]
    • GEICO1601-ROLANDO: a multicentric single arm Phase II clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer.
    • Perez-Fidalgo JA, Iglesias M, Bohn U, Calvo E, Garcia Y, Guerra E, Manso L, Santaballa A, Gonzalez-Martin A.
    • Future Sci OA. 2019 Jan 10;5(2):FSO370. doi: 10.4155/fsoa-2018-0107. eCollection 2019 Feb.
    • Synchronous Ovarian and Breast Cancers with a Novel Variant in BRCA2 Gene: A Case Report.
    • Llinás-Quintero N, Cabrera-Florez E, Mendoza-Fandiño G, Matute-Turizo G, Vasquez-Trespalacios EM, Gallón-Villegas LJ.
    • Case Rep Oncol Med. 2019 Jan 6;2019:6958952. doi: 10.1155/2019/6958952. eCollection 2019.
    • PARP Inhibitor Olaparib Use in a BRCA1-Positive Patient With Metastatic Triple-Negative Breast Cancer, Without the Initial Use of Platinum-Based Chemotherapy, Showing Significant Rapid Near Resolution of Large Liver Metastasis While Patient Experienced Gout-Like Symptoms.
    • Matthews Hew T, Zuberi L.
    • J Investig Med High Impact Case Rep. 2019 Jan-Dec;7:2324709619864989. doi: 10.1177/2324709619864989.
    • The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer.
    • Hjortkjær M, Malik Aagaard Jørgensen M, Waldstrøm M, Ørnskov D, Søgaard-Andersen E, Jakobsen A, Dahl-Steffensen K.
    • Int J Gynecol Cancer. 2019 Jan;29(1):166-173. doi: 10.1136/ijgc-2018-000017.
    • Exploring and comparing adverse events between PARP inhibitors.
    • LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL.
    • Lancet Oncol. 2019 Jan;20(1):e15-e28. doi: 10.1016/S1470-2045(18)30786-1.
    • Review
    • Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
    • Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P.
    • N Engl J Med. 2018 Dec 27;379(26):2495-2505. doi: 10.1056/NEJMoa1810858. Epub 2018 Oct 21.

    Editorial:

    Progress in BRCA-Mutated Ovarian Cancer.

    • Sequence kernel association test for survival outcomes in the presence of a non-susceptible fraction.
    • Lakhal-Chaieb L, Simard J, Bull S.
    • Biostatistics. 2018 Dec 26. doi: 10.1093/biostatistics/kxy075. [Epub ahead of print]
    • Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors.
    • Faraoni I, Graziani G.
    • Cancers (Basel). 2018 Dec 4;10(12). pii: E487. doi: 10.3390/cancers10120487.
    • Distinct Clinical Courses of Epithelial Ovarian Cancer with Mutations in BRCA1 5' and 3' Exons.
    • Eoh KJ, Park HS, Park JS, Lee ST, Han JW, Lee JY, Kim S, Kim SW, Kim YT, Nam EJ.
    • Anticancer Res. 2018 Dec;38(12):6947-6953. doi: 10.21873/anticanres.13073.
    • Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease.
    • Dal Molin GZ, Westin SN, Coleman RL.
    • Future Oncol. 2018 Dec;14(30):3101-3110. doi: 10.2217/fon-2018-0215. Epub 2018 Aug 14.
    • Review
    • Patients with BRCA mutations have superior outcomes after intraperitoneal chemotherapy in optimally resected high grade ovarian cancer.
    • Naumann RW, Morris JC, Tait DL, Higgins RV, Crane EK, Drury LK, Amacker-North L, Templin M, Brown J.
    • Gynecol Oncol. 2018 Dec;151(3):477-480. doi: 10.1016/j.ygyno.2018.10.003. Epub 2018 Oct 8.
    • Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancer.
    • Altwerger G, Florsheim EB, Menderes G, Black J, Schwab C, Gressel GM, Nelson WK, Carusillo N, Passante T, Huang G, Litkouhi B, Azodi M, Silasi DA, Santin A, Schwartz PE, Ratner ES.
    • J Cancer Res Clin Oncol. 2018 Dec;144(12):2449-2456. doi: 10.1007/s00432-018-2753-y. Epub 2018 Sep 25.
    • Maintenance olaparib in advanced ovarian cancer.
    • Burki TK.
    • Lancet Oncol. 2018 Dec;19(12):e671. doi: 10.1016/S1470-2045(18)30816-7. Epub 2018 Oct 25.
    • Research news
    • Real-World Use and Outcomes of Olaparib: a Population-Based Cohort Study.
    • Eriksson I, Wettermark B, Bergfeldt K.
    • Target Oncol. 2018 Dec;13(6):725-733. doi: 10.1007/s11523-018-0604-z.
    • Olaparib Tablet: A Review in Ovarian Cancer Maintenance Therapy.
    • Heo YA, Dhillon S.
    • Target Oncol. 2018 Dec;13(6):801-808. doi: 10.1007/s11523-018-0606-x.
    • Review
    • Association between CT-texture-derived tumor heterogeneity, outcomes, and BRCA mutation status in patients with high-grade serous ovarian cancer.
    • Meier A, Veeraraghavan H, Nougaret S, Lakhman Y, Sosa R, Soslow RA, Sutton EJ, Hricak H, Sala E, Vargas HA.
    • Abdom Radiol (NY). 2018 Nov 24. doi: 10.1007/s00261-018-1840-5. [Epub ahead of print]
    • An Unusual Adenomatoid Tumor of Fimbria with Pronounced Psammoma Bodies in a BRCA Positive Patient as a Pitfall for Carcinoma on Frozen Section.
    • Lee CM, Moh M, Sullivan PS, Moatamed NA.
    • Case Rep Pathol. 2018 Nov 21;2018:8148147. doi: 10.1155/2018/8148147. eCollection 2018.
    • How safe is rucaparib in ovarian cancer?
    • Cosgrove CM, O'Malley DM.
    • Expert Opin Drug Saf. 2018 Nov 19. doi: 10.1080/14740338.2018.1550067. [Epub ahead of print]
    • Review
    • Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.
    • Kurnit KC, Coleman RL, Westin SN.
    • Curr Treat Options Oncol. 2018 Nov 15;19(12):1. doi: 10.1007/s11864-018-0572-7.
    • Review
    • Targeted treatment of advanced ovarian cancer: spotlight on rucaparib.
    • Pearre DC, Tewari KS.
    • Ther Clin Risk Manag. 2018 Nov 2;14:2189-2201. doi: 10.2147/TCRM.S149248. eCollection 2018.
    • Defective DNA repair in hereditary ovarian cancers: Implications for therapy.
    • Burgess BT, Kolesar JM.
    • Am J Health Syst Pharm. 2018 Nov 1;75(21):1697-1707. doi: 10.2146/ajhp180124. Epub 2018 Sep 18.
    • Review
    • BRCA Mutation Status to Personalize Management of Recurrent Ovarian Cancer: A Multicenter Study.
    • Marchetti C, De Leo R, Musella A, D'Indinosante M, Capoluongo E, Minucci A, Benedetti Panici P, Scambia G, Fagotti A.
    • Ann Surg Oncol. 2018 Nov;25(12):3701-3708. doi: 10.1245/s10434-018-6700-6. Epub 2018 Aug 20.

    Commentary:

    ASO Author Reflections: BRCA Mutation Status for Personalizing Management of Recurrent Ovarian Cancer-A Multicenter Study.

    • Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.
    • Hodgson DR, Dougherty BA, Lai Z, Fielding A, Grinsted L, Spencer S, O'Connor MJ, Ho TW, Robertson JD, Lanchbury JS, Timms KM, Gutin A, Orr M, Jones H, Gilks B, Womack C, Gourley C, Ledermann J, Barrett JC.
    • Br J Cancer. 2018 Nov;119(11):1401-1409. doi: 10.1038/s41416-018-0274-8. Epub 2018 Oct 24.
    • The Era of PARP inhibitors in ovarian cancer: "Class Action" or not? A systematic review and meta-analysis.
    • Staropoli N, Ciliberto D, Del Giudice T, Iuliano E, Cucè M, Grillone F, Salvino A, Barbieri V, Russo A, Tassone P, Tagliaferri P.
    • Crit Rev Oncol Hematol. 2018 Nov;131:83-89. doi: 10.1016/j.critrevonc.2018.08.011. Epub 2018 Sep 3.
    • Radiomics of high-grade serous ovarian cancer: association between quantitative CT features, residual tumour and disease progression within 12 months.
    • Rizzo S, Botta F, Raimondi S, Origgi D, Buscarino V, Colarieti A, Tomao F, Aletti G, Zanagnolo V, Del Grande M, Colombo N, Bellomi M.
    • Eur Radiol. 2018 Nov;28(11):4849-4859. doi: 10.1007/s00330-018-5389-z. Epub 2018 May 8.
    • 19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes.
    • Aziz D, Etemadmoghadam D, Caldon CE, Au-Yeung G, Deng N, Hutchinson R; Australian Ovarian Cancer Study Group, Bowtell D, Waring P.
    • Gynecol Oncol. 2018 Nov;151(2):327-336. doi: 10.1016/j.ygyno.2018.08.039. Epub 2018 Sep 9.
    • Survival of Women With Type I and II Epithelial Ovarian Cancer Detected by Ultrasound Screening.
    • van Nagell JR Jr, Burgess BT, Miller RW, Baldwin L, DeSimone CP, Ueland FR, Huang B, Chen Q, Kryscio RJ, Pavlik EJ.
    • Obstet Gynecol. 2018 Nov;132(5):1091-1100. doi: 10.1097/AOG.0000000000002921.

    Editorial, Research news:

    Ultrasound Screening for Ovarian Cancer: Are We There Yet?

    • Pharmacokinetics and clinical response to single agent rucaparib in a dialysis dependent patient with BRCA associated breast and recurrent ovarian cancer.
    • Harold JA, Free SC, Bradley WH.
    • Gynecol Oncol Rep. 2018 Oct 28;26:91-93. doi: 10.1016/j.gore.2018.10.011. eCollection 2018 Nov.
    • Long-term mortality among women with epithelial ovarian cancer: a population-based study in British Columbia, Canada.
    • Arora N, Talhouk A, McAlpine JN, Law MR, Hanley GE.
    • BMC Cancer. 2018 Oct 25;18(1):1039. doi: 10.1186/s12885-018-4970-9.
    • Development of a Novel Autophagy-related Prognostic Signature for Serous Ovarian Cancer.
    • An Y, Bi F, You Y, Liu X, Yang Q.
    • J Cancer. 2018 Oct 18;9(21):4058-4071. doi: 10.7150/jca.25587. eCollection 2018.
    • Serous ovarian carcinoma in patients with Lynch syndrome: Caution is warranted.
    • Benusiglio PR, Coulet F.
    • Gynecol Oncol Rep. 2018 Oct 12;26:69-70. doi: 10.1016/j.gore.2018.10.005. eCollection 2018 Nov.

    Original research:

    Characteristics of Lynch syndrome associated ovarian cancer.

    • Familial risks of second primary cancers and mortality in ovarian cancer patients.
    • Zheng G, Chattopadhyay S, Försti A, Sundquist K, Hemminki K.
    • Clin Epidemiol. 2018 Oct 11;10:1457-1466. doi: 10.2147/CLEP.S174173. eCollection 2018.
    • Clinical and Genetic Characteristics of BRCA1/2 Mutation in Korean Ovarian Cancer Patients: A Multicenter Study and Literature Review.
    • Kwon BS, Byun JM, Lee HJ, Jeong DH, Lee TH, Shin KH, Suh DS, Kim KH.
    • Cancer Res Treat. 2018 Oct 8. doi: 10.4143/crt.2018.312. [Epub ahead of print]
    • Niraparib - A promising drug with hematological toxicity.
    • Patibandla NS, Monga DK.
    • J Oncol Pharm Pract. 2018 Oct 6:1078155218800156. doi: 10.1177/1078155218800156. [Epub ahead of print]
    • Case report
    • Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy.
    • Friedlander M, Matulonis U, Gourley C, du Bois A, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Shirinkin V, Selle F, Fielding A, Lowe ES, McMurtry EL, Spencer S, Rowe P, Mann H, Parry D, Ledermann J.
    • Br J Cancer. 2018 Oct;119(9):1075-1085. doi: 10.1038/s41416-018-0271-y. Epub 2018 Oct 24.

    Press: 'Outstanding' Ovarian Cancer PFS With Olaparib Maintenance. (Medscape Oncology)

    • Olaparib for the treatment of relapsed ovarian cancer with a BRCA1/2 mutation.
    • Stewart J, George A, Banerjee S.
    • Expert Rev Anticancer Ther. 2018 Oct;18(10):947-958. doi: 10.1080/14737140.2018.1510323. Epub 2018 Aug 24.
    • Review
    • Efficacy of Neoadjuvant Therapy With Cisplatin Plus Mitomycin C in BRCA1-Mutated Ovarian Cancer.
    • Gorodnova TV, Kotiv KB, Ivantsov AO, Mikheyeva ON, Mikhailiuk GI, Lisyanskaya AS, Mikaya NA, Guseynov KD, Bondarev NE, Matveyeva NS, Nekrasova EA, Sidoruk AA, Roman LD, Manikhas GM, Belyaev AM, Sokolenko AP, Berlev IV, Imyanitov EN.
    • Int J Gynecol Cancer. 2018 Oct;28(8):1498-1506. doi: 10.1097/IGC.0000000000001352.
    • A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.
    • van der Biessen DAJ, Gietema JA, de Jonge MJA, Desar IME, den Hollander MW, Dudley M, Dunbar M, Hetman R, Serpenti C, Xiong H, Mittapalli RK, Timms KM, Ansell P, Ratajczak CK, Shepherd SP, van Herpen CML.
    • Invest New Drugs. 2018 Oct;36(5):828-835. doi: 10.1007/s10637-017-0551-z. Epub 2018 Jan 8.
    • Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.
    • Kondrashova O, Topp M, Nesic K, Lieschke E, Ho GY, Harrell MI, Zapparoli GV, Hadley A, Holian R, Boehm E, Heong V, Sanij E, Pearson RB, Krais JJ, Johnson N, McNally O, Ananda S, Alsop K, Hutt KJ, Kaufmann SH, Lin KK, Harding TC, Traficante N; Australian Ovarian Cancer Study (AOCS), deFazio A, McNeish IA, Bowtell DD, Swisher EM, Dobrovic A, Wakefield MJ, Scott CL.
    • Nat Commun. 2018 Sep 28;9(1):3970. doi: 10.1038/s41467-018-05564-z.
    • A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer Patients.
    • Tumiati M, Hietanen S, Hynninen J, Pietilä E, Färkkilä A, Kaipio K, Roering P, Huhtinen K, Alkodsi A, Li Y, Lehtonen R, Erkan EP, Tuominen MM, Lehti K, Hautaniemi SK, Vähärautio A, Grénman S, Carpén O, Kauppi L.
    • Clin Cancer Res. 2018 Sep 15;24(18):4482-4493. doi: 10.1158/1078-0432.CCR-17-3770. Epub 2018 Jun 1.
    • PARP Inhibitors in Ovarian Cancer: A Trailblazing and Transformative Journey.
    • Konstantinopoulos PA, Matulonis UA.
    • Clin Cancer Res. 2018 Sep 1;24(17):4062-4065. doi: 10.1158/1078-0432.CCR-18-1314. Epub 2018 Jun 5.
    • Commentary, Review

    Review:

    FDA Approval Summary: Niraparib for the maintenance treatment of patients with recurrent ovarian cancer in response to platinum-based chemotherapy.

    • FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy.
    • Ison G, Howie LJ, Amiri-Kordestani L, Zhang L, Tang S, Sridhara R, Pierre V, Charlab R, Ramamoorthy A, Song P, Li F, Yu J, Manheng W, Palmby TR, Ghosh S, Horne HN, Lee EY, Philip R, Dave K, Chen XH, Kelly SL, Janoria KG, Banerjee A, Eradiri O, Dinin J, Goldberg KB, Pierce WF, Ibrahim A, Kluetz PG, Blumenthal GM, Beaver JA, Pazdur R.
    • Clin Cancer Res. 2018 Sep 1;24(17):4066-4071. doi: 10.1158/1078-0432.CCR-18-0042. Epub 2018 Apr 12.
    • Review

    Commentary, Review:

    PARP inhibitors in ovarian cancer: a trailblazing and transformative journey.

    • Clinicopathologic features and BRCA mutations in primary fallopian tube cancer in Japanese women.
    • Sakurada S, Watanabe Y, Tokunaga H, Takahashi F, Yamada H, Takehara K, Yaegashi N.
    • Jpn J Clin Oncol. 2018 Sep 1;48(9):794-798. doi: 10.1093/jjco/hyy095.
    • BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer.
    • Tsibulak I, Wieser V, Degasper C, Shivalingaiah G, Wenzel S, Sprung S, Lax SF, Marth C, Fiegl H, Zeimet AG.
    • Br J Cancer. 2018 Sep;119(6):683-692. doi: 10.1038/s41416-018-0217-4. Epub 2018 Aug 15.
    • Clinical outcomes of adolescents and young adults with advanced solid tumours participating in phase I trials.
    • Sundar R, McVeigh T, Dolling D, Petruckevitch A, Diamantis N, Ang JE, Chenard-Poiriér M, Collins D, Lim J, Ameratunga M, Khan K, Kaye SB, Banerji U, Lopez J, George AJ, de Bono JS, van der Graaf WT.
    • Eur J Cancer. 2018 Sep;101:55-61. doi: 10.1016/j.ejca.2018.06.003. Epub 2018 Jul 17.
    • Evaluation of Microscopic Changes in Fallopian Tubes of BRCA Mutation Carriers by Morphometric Analysis of Histologic Slides: A Preliminary Pilot Study.
    • Amit A, Sabo E, Zohar Y, Trugman E, Pranovich I, Reiss A, Matanes E, Klorin G.
    • Int J Gynecol Pathol. 2018 Sep;37(5):460-467. doi: 10.1097/PGP.0000000000000440.
    • Poly (ADP-ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: A Drug Class Review.
    • Ringley JT, Moore DC, Patel J, Rose MS.
    • P T. 2018 Sep;43(9):549-556.
    • Surgery for BRCA, TP53 and PALB2: a literature review.
    • Song CV, Teo SH, Taib NA, Yip CH.
    • Ecancermedicalscience. 2018 Aug 29;12:863. doi: 10.3332/ecancer.2018.863. eCollection 2018.
    • The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials.
    • Guo XX, Wu HL, Shi HY, Su L, Zhang X.
    • Cancer Manag Res. 2018 Aug 10;10:2553-2562. doi: 10.2147/CMAR.S169558. eCollection 2018.
    • Immunogenomic Analyses of Advanced Serous Ovarian Cancer Reveal Immune Score is a Strong Prognostic Factor and an Indicator of Chemosensitivity.
    • Hao D, Liu J, Chen M, Li J, Wang L, Li X, Zhao Q, Di LJ.
    • Clin Cancer Res. 2018 Aug 1;24(15):3560-3571. doi: 10.1158/1078-0432.CCR-17-3862. Epub 2018 Apr 16.
    • Outcome and Prognostic Impact of Surgical Staging in Serous Tubal Intraepithelial Carcinoma: A Cohort Study and Systematic Review.
    • Van der Hoeven NMA, Van Wijk K, Bonfrer SE, Beltman JJ, Louwe LA, De Kroon CD, Van Asperen CJ, Gaarenstroom KN.
    • Clin Oncol (R Coll Radiol). 2018 Aug;30(8):463-471. doi: 10.1016/j.clon.2018.03.036. Epub 2018 Apr 22.
    • Trabectedin in Ovarian Cancer: is it now a Standard of Care?
    • Ventriglia J, Paciolla I, Cecere SC, Pisano C, Di Napoli M, Arenare L, Setola SV, Losito NS, Califano D, Orditura M, Pignata S.
    • Clin Oncol (R Coll Radiol). 2018 Aug;30(8):498-503. doi: 10.1016/j.clon.2018.01.008. Epub 2018 Feb 9.
    • Review
    • Characteristics of Lynch syndrome associated ovarian cancer.
    • Woolderink JM, De Bock GH, de Hullu JA, Hollema H, Zweemer RP, Slangen BFM, Gaarenstroom KN, van Beurden M, van Doorn HC, Sijmons RH, Vasen HFA, Mourits MJE.
    • Gynecol Oncol. 2018 Aug;150(2):324-330. doi: 10.1016/j.ygyno.2018.03.060. Epub 2018 Jun 5.

    Letter, Commentary:

    Serous ovarian carcinoma in patients with Lynch syndrome: Caution is warranted.

    • Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial.
    • Oza AM, Matulonis UA, Malander S, Hudgens S, Sehouli J, Del Campo JM, Berton-Rigaud D, Banerjee S, Scambia G, Berek JS, Lund B, Tinker AV, Hilpert F, Vázquez IP, D'Hondt V, Benigno B, Provencher D, Buscema J, Agarwal S, Mirza MR.
    • Lancet Oncol. 2018 Aug;19(8):1117-1125. doi: 10.1016/S1470-2045(18)30333-4. Epub 2018 Jul 17.

    Research news:

    PARP inhibitors and quality of life in ovarian cancer.

    • Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial.
    • Friedlander M, Gebski V, Gibbs E, Davies L, Bloomfield R, Hilpert F, Wenzel LB, Eek D, Rodrigues M, Clamp A, Penson RT, Provencher D, Korach J, Huzarski T, Vidal L, Salutari V, Scott C, Nicoletto MO, Tamura K, Espinoza D, Joly F, Pujade-Lauraine E.
    • Lancet Oncol. 2018 Aug;19(8):1126-1134. doi: 10.1016/S1470-2045(18)30343-7. Epub 2018 Jul 17.

    Research news:

    PARP inhibitors and quality of life in ovarian cancer.

    • Comparative clinicopathological and cytomorphological analyses of peritoneal carcinomatosis associated with metastatic breast carcinoma and primary peritoneal/ovarian carcinoma in patients with a history of breast carcinoma.
    • Na K, Lee JY, Sung JY, Kim GM, Koo JS, Kim HS.
    • Virchows Arch. 2018 Aug;473(2):165-175. doi: 10.1007/s00428-018-2390-5. Epub 2018 Jun 20.
    • BRCA Status Does Not Predict Synergism of a Carboplatin and Olaparib Combination in High-Grade Serous Ovarian Cancer Cell Lines.
    • Shen YT, Evans JC, Zafarana G, Allen C, Piquette-Miller M.
    • Mol Pharm. 2018 Jul 2;15(7):2742-2753. doi: 10.1021/acs.molpharmaceut.8b00246. Epub 2018 Jun 1.
    • Intra-operative evaluation of prophylactic hysterectomy and salpingo-oophorectomy specimens in hereditary gynaecological cancer syndromes.
    • Wong S, Ratner E, Buza N.
    • Histopathology. 2018 Jul;73(1):109-123. doi: 10.1111/his.13503. Epub 2018 Apr 16.
    • Biomarker Assessment of HR Deficiency, Tumor BRCA1/2 Mutations, and CCNE1 Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy.
    • Stronach EA, Paul J, Timms KM, Hughes E, Brown K, Neff C, Perry M, Gutin A, El-Bahrawy M, Steel JH, Liu X, Lewsley LA, Siddiqui N, Gabra H, Lanchbury JS, Brown R.
    • Mol Cancer Res. 2018 Jul;16(7):1103-1111. doi: 10.1158/1541-7786.MCR-18-0034. Epub 2018 May 3.
    • Nivolumab use for BRCA gene mutation carriers with recurrent epithelial ovarian cancer: A case series.
    • Matsuo K, Spragg SE, Ciccone MA, Blake EA, Ricker C, Pham HQ, Roman LD.
    • Gynecol Oncol Rep. 2018 Jun 20;25:98-101. doi: 10.1016/j.gore.2018.06.011. eCollection 2018 Aug.
    • Immunogenomic Analyses of Advanced Serous Ovarian Cancer Reveal Immune Score is a Strong Prognostic Factor and an Indicator of Chemosensitivity.
    • Hao D, Liu J, Chen M, Li J, Wang L, Li X, Zhao Q, Di L
    • Clin Cancer Res. 2018 Jun 12. doi: 10.1158/1078-0432.CCR-17-3862. [Epub ahead of print]
    • High-resolution melting analysis coupled with next-generation sequencing as a simple tool for the identification of a novel somatic BRCA2 variant: a case report.
    • Costella A, De Leo R, Guarino D, D'Indinosante M, Concolino P, Mazzuccato G, Urbani A, Scambia G, Capoluongo E, Fagotti A, Minucci A.
    • Hum Genome Var. 2018 Jun 8;5:10. doi: 10.1038/s41439-018-0006-x. eCollection 2018.
    • Latest clinical evidence and further development of PARP inhibitors in ovarian cancer.
    • Mirza MR, Pignata S, Ledermann JA.
    • Ann Oncol. 2018 Jun 1;29(6):1366-1376. doi: 10.1093/annonc/mdy174.
    • Safety and pharmacokinetics of veliparib extended-release in patients with advanced solid tumors: a phase I study.
    • Werner TL, Sachdev J, Swisher EM, Gutierrez M, Kittaneh M, Stein MN, Xiong H, Dunbar M, Sullivan D, Komarnitsky P, McKee M, Tan AR.
    • Cancer Med. 2018 Jun;7(6):2360-2369. doi: 10.1002/cam4.1488. Epub 2018 May 7.
    • Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations.
    • Moore KN, Birrer MJ.
    • Oncologist. 2018 Jun;23(6):697-703. doi: 10.1634/theoncologist.2017-0485. Epub 2018 Mar 28.
    • Review
    • Potent immunogenicity in BRCA1-mutated patients with high-grade serous ovarian carcinoma.
    • Dai Y, Sun C, Feng Y, Jia Q, Zhu B.
    • J Cell Mol Med. 2018 May 31. doi: 10.1111/jcmm.13678. [Epub ahead of print]
    • Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy.
    • Lorusso D, Tripodi E, Maltese G, Lepori S, Sabatucci I, Bogani G, Raspagliesi F.
    • Drug Des Devel Ther. 2018 May 29;12:1501-1509. doi: 10.2147/DDDT.S124447. eCollection 2018.
    • Role of Poly Adenosine Diphosphate Ribose Polymerase Inhibitors in Advanced Stage Ovarian Cancer.
    • Arora E, Masab M, Jindal V, Riaz I, Gupta S, Varadi G.
    • Cureus. 2018 May 24;10(5):e2685. doi: 10.7759/cureus.2685.
    • Next-generation sequencing unravels extensive genetic alteration in recurrent ovarian cancer and unique genetic changes in drug-resistant recurrent ovarian cancer.
    • Du ZH, Bi FF, Wang L, Yang Q.
    • Mol Genet Genomic Med. 2018 May 24. doi: 10.1002/mgg3.414. [Epub ahead of print]
    • Complete response to orally administered melphalan in malignant pleural effusion from an occult female genital organ primary neoplasm with BRCA1/2 mutations: a case report.
    • Fan FS, Yang CF.
    • J Med Case Rep. 2018 May 6;12(1):122. doi: 10.1186/s13256-018-1674-3.
    • RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.
    • Cruz C, Castroviejo-Bermejo M, Gutiérrez-Enríquez S, Llop-Guevara A, Ibrahim YH, Gris-Oliver A, Bonache S, Morancho B, Bruna A, Rueda OM, Lai Z, Polanska UM, Jones GN, Kristel P, de Bustos L, Guzman M, Rodríguez O, Grueso J, Montalban G, Caratú G, Mancuso F, Fasani R, Jiménez J, Howat WJ, Dougherty B, Vivancos A, Nuciforo P, Serres-Créixams X, Rubio IT, Oaknin A, Cadogan E, Barrett JC, Caldas C, Baselga J, Saura C, Cortés J, Arribas J, Jonkers J, Díez O, O'Connor MJ, Balmaña J, Serra V.
    • Ann Oncol. 2018 May 1;29(5):1203-1210. doi: 10.1093/annonc/mdy099.
    • Clinical study of hereditary ovarian cancer syndrome in Shandong province, East China.
    • Sheng X, Zhong Y, Lu C, Peng J, Yu H, Guo J.
    • Int J Gynaecol Obstet. 2018 May;141(2):234-239. doi: 10.1002/ijgo.12447. Epub 2018 Feb 14.
    • BRCAmut and "founder effect": a prospective study in a single academic institution.
    • Loizzi V, Cicinelli E, Santamaria F, Murgia F, Minicucci V, Resta L, Resta N, Natalicchio MI, Ranieri G, Cormio G.
    • Oncotarget. 2018 Apr 27;9(32):22353-22358. doi: 10.18632/oncotarget.24959. eCollection 2018 Apr 27.
    • Olaparib in Breast Cancer: PFS Is Significant but OS Is Not.
    • Castellino AM.
    • Medscape. Medscape Medical News. 2018 Apr 18.
    • The clinical impact of serous tubal intraepithelial carcinoma on outcomes of patients with high-grade serous carcinoma of the ovary, fallopian tube, and peritoneum.
    • Toptas T, Pestereli E, Simsek T, Bozkurt S, Erdogan G, Karaveli S.
    • J Cancer Res Ther. 2018 Apr-Jun;14(3):587-592. doi: 10.4103/0973-1482.172130.
    • The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities.
    • Moore KN, Mirza MR, Matulonis UA.
    • Gynecol Oncol. 2018 Apr;149(1):214-220. doi: 10.1016/j.ygyno.2018.01.011. Epub 2018 Feb 4.
    • Review
    • Systematic analysis reveals a lncRNA-mRNA co-expression network associated with platinum resistance in high-grade serous ovarian cancer.
    • Fang L, Wang H, Li P.
    • Invest New Drugs. 2018 Apr;36(2):187-194. doi: 10.1007/s10637-017-0523-3. Epub 2017 Oct 30.
    • Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers.
    • Le Page C, Rahimi K, Köbel M, Tonin PN, Meunier L, Portelance L, Bernard M, Nelson BH, Bernardini MQ, Bartlett JMS, Bachvarov D, Gotlieb WH, Gilks B, McAlpine JN, Nachtigal MW, Piché A, Watson PH, Vanderhyden B, Huntsman DG, Provencher DM, Mes-Masson AM.
    • BMC Cancer. 2018 Mar 27;18(1):347. doi: 10.1186/s12885-018-4242-8.
    • Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
    • Oaknin A, Guarch R, Barretina P, Hardisson D, González A, Matías-Guiu X, Pérez-Fidalgo A, Vieites B, Romero I, Palacios J.
    • Clin Transl Oncol. 2018 Mar;20(3):274-285. doi: 10.1007/s12094-017-1719-x. Epub 2017 Aug 16.
    • Claudin-4 Expression is Associated With Survival in Ovarian Cancer But Not With Chemotherapy Response.
    • Martín de la Fuente L, Malander S, Hartman L, Jönsson JM, Ebbesson A, Nilbert M, Måsbäck A, Hedenfalk I.
    • Int J Gynecol Pathol. 2018 Mar;37(2):101-109. doi: 10.1097/PGP.0000000000000394.
    • Could ALDH2*2 be the reason for low incidence and mortality of ovarian cancer for East Asia women?
    • Yan S, Wu G.
    • Oncotarget. 2017 Dec 22;9(15):12503-12512. doi: 10.18632/oncotarget.23605. eCollection 2018 Feb 23.
    • Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: an NRG Oncology/Gynecologic Oncology Group Study.
    • Norquist BM, Brady MF, Harrell MI, Walsh T, Lee MK, Gulsuner S, Bernards SS, Casadei S, Burger RA, Tewari KS, Backes FJ, Mannel RS, Glaser G, Bailey C, Rubin SC, Soper JT, Lankes HA, Ramirez NC, King MC, Birrer MJ, Swisher EM.
    • Clin Cancer Res. 2018 Feb 15;24(4):777-783. doi: 10.1158/1078-0432.CCR-17-1327. Epub 2017 Nov 30.
    • Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma.
    • Bernards SS, Pennington KP, Harrell MI, Agnew KJ, Garcia RL, Norquist BM, Swisher EM.
    • Gynecol Oncol. 2018 Feb;148(2):281-285. doi: 10.1016/j.ygyno.2017.12.004. Epub 2017 Dec 9.
    • Location of mutation in BRCA2 gene and survival in patients with ovarian cancer.
    • Labidi-Galy SI, Olivier T, Rodrigues M, Ferraioli D, Bodmer A, Petignat P, Rak B, Chopin N, Tredan O, Heudel PE, Stuckelberger SJ, Meeus P, Meraldi P, Viassolo V, Ayme A, Chappuis PO, Stern MH, Houdayer C, Stoppa-Lyonnet D, Buisson A, Golmard L, Bonadona V, Ray-Coquard I.
    • Clin Cancer Res. 2018 Jan 15;24(2):326-333. doi: 10.1158/1078-0432.CCR-17-2136. Epub 2017 Oct 30.
    • Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
    • Gray HJ, Bell-McGuinn K, Fleming GF, Cristea M, Xiong H, Sullivan D, Luo Y, McKee MD, Munasinghe W, Martin LP.
    • Gynecol Oncol. 2018 Jan 15. pii: S0090-8258(17)31620-7. doi: 10.1016/j.ygyno.2017.12.029. [Epub ahead of print]
    • Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations.
    • Hollis RL, Meynert AM, Churchman M, Rye T, Mackean M, Nussey F, Arends MJ, Sims AH, Semple CA, Herrington CS, Gourley C.
    • BMC Cancer. 2018 Jan 3;18(1):16. doi: 10.1186/s12885-017-3981-2.
    • A Novel Model to Characterize Structure and Function of BRCA1.
    • Lin D, Izadpanah R, Braun SE, Alt E.
    • Cell Biol Int. 2018 Jan;42(1):34-44. doi: 10.1002/cbin.10846. Epub 2017 Oct 25.
    • BRCA Mutation Status Is Not Associated With Increased Hematologic Toxicity Among Patients Undergoing Platinum-Based Chemotherapy for Ovarian Cancer.
    • Kotsopoulos J, Willows K, Trat S, Kim RH, Volenik A, Sun P, Narod SA, Boyd J, May T.
    • Int J Gynecol Cancer. 2018 Jan;28(1):69-76. doi: 10.1097/IGC.0000000000001144.
    • Association of BRCA1/2 mutations with ovarian cancer prognosis: An updated meta-analysis.
    • Huang YW.
    • Medicine (Baltimore). 2018 Jan;97(2):e9380. doi: 10.1097/MD.0000000000009380.
    • Successful maintenance therapy with apatinib inplatinum-resistant advanced ovarian cancer and literature review.
    • Jin M, Cai J, Wang X, Zhang T, Zhao Y.
    • Cancer Biol Ther. 2018;19(12):1088-1092. doi: 10.1080/15384047.2018.1491500. Epub 2018 Aug 15.
    • Case report
    • Survival Benefit of Germline BRCA Mutation is Associated with Residual Disease in Ovarian Cancer.
    • Shi T, Wang P, Tang W, Jiang R, Yin S, Shi D, Wang Q, Wei Q, Zang R.
    • Cell Physiol Biochem. 2018;47(5):2088-2096. doi: 10.1159/000491477. Epub 2018 Jul 5.
    • Emerging treatment options for ovarian cancer: focus on rucaparib.
    • Mariappan L, Jiang XY, Jackson J, Drew Y.
    • Int J Womens Health. 2017 Dec 15;9:913-924. doi: 10.2147/IJWH.S151194. eCollection 2017.
    • Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.
    • Ovarian Tumor Tissue Analysis (OTTA) Consortium, Goode EL, Block MS, Kalli KR, Vierkant RA, Chen W, Fogarty ZC, Gentry-Maharaj A, Toloczko A, Hein A, Bouligny AL, Jensen A, Osorio A, Hartkopf AD, Ryan A, Chudecka-Glaz A, Magliocco AM, Hartmann A, Jung AY, Gao B, Hernandez BY, Fridley BL, McCauley BM, Kennedy CJ, Wang C, Karpinskyj C, de Sousa CB, Tiezzi DG, Wachter DL, Herpel E, Taran FA, Modugno F, Nelson G, Lubinski J, Menkiszak J, Alsop J, Lester J, García-Donas J, Nation J, Hung J, Palacios J, Rothstein JH, Kelley JL, de Andrade JM, Robles-Díaz L, Intermaggio MP, Widschwendter M, Beckmann MW, Ruebner M, Jimenez-Linan M, Singh N, Oszurek O, Harnett PR, Rambau PF, Sinn P, Wagner P, Ghatage P, Sharma R, Edwards RP, Ness RB, Orsulic S, Brucker SY, Johnatty SE, Longacre TA, Eilber U, McGuire V, Sieh W, Natanzon Y, Li Z, Whittemore AS, deFazio A, Staebler A, Karlan BY, Gilks B, Bowtell DD, Høgdall E, Candido Dos Reis FJ, Steed H, Campbell IG, Gronwald J, Benítez J, Koziak JM, Chang-Claude J, Moysich KB, Kelemen LE, Cook LS, Goodman MT, García MJ, Fasching PA, Kommoss S, Deen S, Kjaer SK, Menon U, Brenton JD, Pharoah PDP, Chenevix-Trench G, Huntsman DG, Winham SJ, Köbel M, Ramus SJ.
    • JAMA Oncol. 2017 Dec 1;3(12):e173290. doi: 10.1001/jamaoncol.2017.3290.
    • High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy.
    • Perez-Lopez R, Roda D, Jimenez B, Brown J, Mateo J, Carreira S, Lopez J, Banerji U, Molife LR, Koh DM, Kaye SB, de Bono JS, Tunariu N, Yap TA.
    • Oncotarget. 2017 Nov 6;8(61):104430-104443. doi: 10.18632/oncotarget.22303. eCollection 2017 Nov 28.
    • Increased single-strand annealing rather than non-homologous end-joining predicts hereditary ovarian carcinoma.
    • Deniz M, Romashova T, Kostezka S, Faul A, Gundelach T, Moreno-Villanueva M, Janni W, Friedl TWP, Wiesmüller L.
    • Oncotarget. 2017 Oct 9;8(58):98660-98676. doi: 10.18632/oncotarget.21720. eCollection 2017 Nov 17.
    • BRCA mutations in the manifestation and treatment of ovarian cancer.
    • Pan Z, Xie X.
    • Oncotarget. 2017 May 30;8(57):97657-97670. doi: 10.18632/oncotarget.18280. eCollection 2017 Nov 14.
    • Checkpoint and PARP inhibitors, for whom and when.
    • Lee JM, Gulley JL.
    • Oncotarget. 2017 Sep 12;8(56):95036-95037. doi: 10.18632/oncotarget.20852. eCollection 2017 Nov 10.
    • Who are the long-term survivors of high grade serous ovarian cancer?
    • Hoppenot C, Eckert MA, Tienda SM, Lengyel E.
    • Gynecol Oncol. 2017 Nov 8. pii: S0090-8258(17)31454-3. doi: 10.1016/j.ygyno.2017.10.032. [Epub ahead of print]
    • Review
    • 'Important' Progress in Gynecologic Cancers: ESMO 2017.
    • Susana Banerjee
    • Medscape. News & Perspective. 2017 Nov 3.
    • Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.
    • Oza AM, Tinker AV, Oaknin A, Shapira-Frommer R, McNeish IA, Swisher EM, Ray-Coquard I, Bell-McGuinn K, Coleman RL, O'Malley DM, Leary A, Chen LM, Provencher D, Ma L, Brenton JD, Konecny GE, Castro CM, Giordano H, Maloney L, Goble S, Lin KK, Sun J, Raponi M, Rolfe L, Kristeleit RS.
    • Gynecol Oncol. 2017 Nov;147(2):267-275. doi: 10.1016/j.ygyno.2017.08.022. Epub 2017 Sep 4.
    • BRCA and lynch syndrome-associated ovarian cancers behave differently.
    • Ryan NAJ, Bolton J, McVey RJ, Evans DG, Crosbie EJ.
    • Gynecol Oncol Rep. 2017 Nov 22;22:108-109. doi: 10.1016/j.gore.2017.11.007. eCollection 2017 Nov.

    Pathological features and clinical behavior of Lynch syndrome-associated ovarian cancer.

    Letter: Ovarian carcinoma histotype in Lynch syndrome. (Gynecologic Oncology Reports)

    • High-Grade Serous Ovarian Cancer: Associations between BRCA Mutation Status, CT Imaging Phenotypes, and Clinical Outcomes.
    • Nougaret S, Lakhman Y, Gönen M, Goldman DA, Miccò M, D'Anastasi M, Johnson SA, Juluru K, Arnold AG, Sosa RE, Soslow RA, Vargas HA, Hricak H, Kauff ND, Sala E.
    • Radiology. 2017 Nov;285(2):472-481. doi: 10.1148/radiol.2017161697. Epub 2017 Jun 16.
    • Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer.
    • Garsed DW, Alsop K, Fereday S, Emmanuel C, Kennedy C, Etemadmoghadam D, Gao B, Gebski V, Garès V, Christie EL, Wouters MC, Milne K, George J, Patch AM, Li J, Mir Arnau G, Semple T, Gadipally SR, Chiew YE, Hendley J, Mikeska T, Zapparoli GV, Amarasinghe K, Grimmond S, Pearson JV, Waddell N, Hung J, Stewart CJR, Sharma R, Allan PE, Rambau PF, Traficante N, McNally O, Mileshkin L, Hamilton AL, Ananda S, Grossi M, Cohen PA, Leung YC, Rome RM, Beale PJ, Blomfield P, Friedlander M, Brand A, Dobrovic A, Köbel M, Harnett P, Nelson BH, Bowtell DDL, DeFazio A.
    • Clin Cancer Res. 2017 Oct 23. pii: clincanres.1621.2017. doi: 10.1158/1078-0432.CCR-17-1621. [Epub ahead of print]
    • Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1).
    • Harter P, Hauke J, Heitz F, Reuss A, Kommoss S, Marmé F, Heimbach A, Prieske K, Richters L, Burges A, Neidhardt G, de Gregorio N, El-Balat A, Hilpert F, Meier W, Kimmig R, Kast K, Sehouli J, Baumann K, Jackisch C, Park-Simon TW, Hanker L, Kröber S, Pfisterer J, Gevensleben H, Schnelzer A, Dietrich D, Neunhöffer T, Krockenberger M, Brucker SY, Nürnberg P, Thiele H, Altmüller J, Lamla J, Elser G, du Bois A, Hahnen E, Schmutzler R.
    • PLoS One. 2017 Oct 20;12(10):e0186043. doi: 10.1371/journal.pone.0186043. eCollection 2017.
    • Re: A paradigm shift in the origin of ovarian cancer: the ovary is no longer to blame: Is the ovary to blame for tubal carcinoma?
    • Fathalla MF.
    • BJOG. 2017 Oct;124(11):1796-1797. doi: 10.1111/1471-0528.14769.

    A paradigm shift in the origin of ovarian cancer: the ovary is no longer to blame.

    • Prognostic impact of germline mutations in inherited cancer syndromes.
    • Corso G, Feroce I, Intra M, Veronesi P, Sacchini V, Bonanni B, Galimberti V.
    • Future Oncol. 2017 Oct;13(24):2125-2127. doi: 10.2217/fon-2017-0296. Epub 2017 Oct 6.
    • Editorial, Review
    • The First Nationwide Multicenter Prevalence Study of Germline BRCA1 and BRCA2 Mutations in Chinese Ovarian Cancer Patients.
    • Wu X, Wu L, Kong B, Liu J, Yin R, Wen H, Li N, Bu H, Feng Y, Li Q, Lu X, Wei J, Zhu X, Mills J, Ellison G, Gutjahr T, Liu Y.
    • Int J Gynecol Cancer. 2017 Oct;27(8):1650-1657. doi: 10.1097/IGC.0000000000001065.
    • Genetic Versus Epigenetic BRCA1 Silencing Pathways: Clinical Effects in Primary Ovarian Cancer Patients: A Study of the Tumor Bank Ovarian Cancer Consortium.
    • Sun T, Ruscito I, Dimitrova D, Chekerov R, Kulbe H, Baron U, Blanchard V, Panici PB, Darb-Esfahani S, Sehouli J, Olek S, Braicu EI.
    • Int J Gynecol Cancer. 2017 Oct;27(8):1658-1665. doi: 10.1097/IGC.0000000000001071.
    • BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
    • Petrillo M, Marchetti C, De Leo R, Musella A, Capoluongo E, Paris I, Benedetti Panici P, Scambia G, Fagotti A.
    • Am J Obstet Gynecol. 2017 Sep;217(3):334.e1-334.e9. doi: 10.1016/j.ajog.2017.05.036. Epub 2017 May 23.
    • Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-grade Ovarian Carcinoma.
    • Kondrashova O, Nguyen M, Shield-Artin K, Tinker AV, Teng NNH, Harrell MI, Kuiper MJ, Ho GY, Barker H, Jasin M, Prakash R, Kass EM, Sullivan MR, Brunette GJ, Bernstein KA, Coleman RL, Floquet A, Friedlander M, Kichenadasse G, O'Malley DM, Oza AM, Sun JX, Robillard L, Maloney L, Bowtell DDL, Giordano H, Wakefield MJ, Kaufmann SH, Simmons AD, Harding TC, Raponi M, McNeish IA, Swisher EM, Lin K, Scott CL.
    • Cancer Discov. 2017 Sep;7(9):984-998. doi: 10.1158/2159-8290.CD-17-0419. Epub 2017 Jun 6.

    Review:

    Reversion Mutations with Clinical Use of PARP Inhibitors: Many Genes, Many Versions.

    • Elevated Serum Level of CA125 Is a Biomarker That Can Be Used to Alter Prognosis Determined by BRCA Mutation and Family History in Ovarian Cancer.
    • Liu W, Wang Z, Ma J, Hou Y, Zhao J, Dong B, Tu S, Wang L, Guo Y.
    • Genet Test Mol Biomarkers. 2017 Sep;21(9):547-554. doi: 10.1089/gtmb.2017.0104. Epub 2017 Aug 11.
    • High-grade serous carcinoma of tubo-ovarian origin: recent developments.
    • Singh N, McCluggage WG, Gilks CB.
    • Histopathology. 2017 Sep;71(3):339-356. doi: 10.1111/his.13248. Epub 2017 Jul 18.
    • Review
    • Young Israeli women with epithelial ovarian cancer: prevalence of BRCA mutations and clinical correlates.
    • Helpman L, Zidan O, Friedman E, Kalfon S, Perri T, Ben-Baruch G, Korach J.
    • J Gynecol Oncol. 2017 Sep;28(5):e61. doi: 10.3802/jgo.2017.28.e61. Epub 2017 Jun 5.
    • BRCA1-mutated ovarian cancer with skin metastasis: a case report.
    • Oh SR, Park JW, Kwon HY, Rha SH.
    • Obstet Gynecol Sci. 2017 Sep;60(5):477-480. doi: 10.5468/ogs.2017.60.5.477. Epub 2017 Sep 18.
    • Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization.
    • Lheureux S, Lai Z, Dougherty BA, Runswick S, Hodgson D, Timms KM, Lanchbury JS, Kaye SB, Gourley C, Bowtell DD, Kohn EC, Scott CL, Matulonis UA, Panzarella T, Karakasis K, Burnier JV, Gilks B, O'Connor MJ, Robertson JD, Ledermann J, Barrett JC, Ho TW, Oza AM.
    • Clin Cancer Res. 2017 Aug 1;23(15):4086-4094. doi: 10.1158/1078-0432.CCR-16-2615. Epub 2017 Feb 21.
    • A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors.
    • Kristeleit R, Shapiro GI, Burris HA, Oza AM, LoRusso PM, Patel M, Domchek SM, Balmaña J, Drew Y, Chen LM, Safra T, Montes A, Giordano H, Maloney L, Goble S, Isaacson J, Xiao J, Borrow J, Rolfe L, Shapira-Frommer R.
    • Clin Cancer Res. 2017 Aug 1;23(15):4095-4106. doi: 10.1158/1078-0432.CCR-16-2796. Epub 2017 Mar 6.
    • Hypoxia-Activated Alkylating Agents in BRCA1-Mutant Ovarian Serous Carcinoma.
    • Conroy M, Borad MJ, Bryce AH.
    • Cureus. 2017 Jul 26;9(7):e1517. doi: 10.7759/cureus.1517.
    • Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
    • Rafii S, Gourley C, Kumar R, Geuna E, Ang JE, Rye T, Chen LM, Shapira-Frommer R, Friedlander M, Matulonis U, De Greve J, Oza AM, Banerjee S, Molife LR, Gore ME, Kaye SB, Yap TA.
    • Oncotarget. 2017 Jul 18;8(29):47154-47160. doi: 10.18632/oncotarget.17005.
    • Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials.
    • Skates SJ, Greene MH, Buys SS, Mai PL, Brown PH, Piedmonte M, Rodriguez GC, Schorge JO, Sherman M, Daly MB, Rutherford TJ, Brewster WR, O'Malley DM, Partridge EE, Boggess J, Drescher CW, Isaacs C, Berchuck A, Domchek SM, Davidson SA, Edwards RP, Elg SA, Wakeley K, Phillips KA, Armstrong DK, Horowitz IR, Fabian CJ, Walker J, Sluss PM, Welch WR, Minasian L, Horick N, Kasten CH, Nayfield S, Alberts DS, Finkelstein DM, Lu K.
    • Clin Cancer Res. 2017 Jul 15;23(14):3628-3637. doi: 10.1158/1078-0432.CCR-15-2750. Epub 2017 Jan 31.
    • Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting.
    • Dougherty BA, Lai Z, Hodgson DR, Orr MCM, Hawryluk M, Sun J, Yelensky R, Spencer SK, Robertson JD, Ho TW, Fielding A, Ledermann JA, Barrett JC.
    • Oncotarget. 2017 Jul 4;8(27):43653-43661. doi: 10.18632/oncotarget.17613.

    Research news:

    Olaparib and somatic BRCA mutations.

    • Rapid selection of BRCA1-proficient tumor cells during neoadjuvant therapy for ovarian cancer in BRCA1 mutation carriers.
    • Sokolenko AP, Savonevich EL, Ivantsov AO, Raskin GA, Kuligina ES, Gorodnova TV, Preobrazhenskaya EV, Kleshchov MA, Tyurin VI, Mukhina MS, Kotiv KB, Shulga AV, Kuznetsov SG, Berlev IV, Imyanitov EN.
    • Cancer Lett. 2017 Jul 1;397:127-132. doi: 10.1016/j.canlet.2017.03.036. Epub 2017 Apr 1.
    • The association between prognosis of breast cancer and first-degree family history of breast or ovarian cancer: a systematic review and meta-analysis.
    • Song JL, Chen C, Yuan JP, Sun SR.
    • Fam Cancer. 2017 Jul;16(3):339-349. doi: 10.1007/s10689-017-9969-x.
    • Review
    • Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer.
    • Bookman MA, Tyczynski JE, Espirito JL, Wilson TW, Fernandes AW.
    • Gynecol Oncol. 2017 Jul;146(1):58-63. doi: 10.1016/j.ygyno.2017.04.011. Epub 2017 Apr 26.
    • Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing.
    • Zhao Q, Yang J, Li L, Cao D, Yu M, Shen K; BGI Group.
    • J Gynecol Oncol. 2017 Jul;28(4):e39. doi: 10.3802/jgo.2017.28.e39.
    • [Association between single nucleotide polymorphism of BARD1 gene and BRCA1 gene mutation in epithelial ovarian cancer].
    • Liu WL, Zhao JZ, Wang ZZ, Dong B, Hou YY, Wu XX, Guo YJ.
    • Zhonghua Fu Chan Ke Za Zhi. 2017 Jun 25;52(6):403-410. doi: 10.3760/cma.j.issn.0529-567X.2017.06.009.
    • English Abstract, [Article in Chinese]
    • Whence High-Grade Serous Ovarian Cancer.
    • Kohn EC, Ivy SP.
    • Am Soc Clin Oncol Educ Book. [Presented Friday, June 2, 2017.] 2017;37:443-448. doi: 10.14694/EDBK_174718.
    • Phase I, Dose-Escalation, 2-Part Trial of Poly(ADP-Ribose) Polymerase Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.
    • de Bono J, Ramanathan RK, Mina L, Chugh R, Glaspy J, Rafii S, Kaye S, Sachdev J, Heymach J, Smith DC, Henshaw JW, Herriott A, Patterson M, Curtin NJ, Byers LA, Wainberg ZA.
    • Cancer Discov. 2017 Jun;7(6):620-629. doi: 10.1158/2159-8290.CD-16-1250. Epub 2017 Feb 27.
    • PARP inhibitors alone and in combination with other biological agents in homologous recombination deficient epithelial ovarian cancer: From the basic research to the clinic.
    • Gadducci A, Guerrieri ME.
    • Crit Rev Oncol Hematol. 2017 Jun;114:153-165. doi: 10.1016/j.critrevonc.2017.04.006. Epub 2017 Apr 20.

    Commentary: 'Clear Role' for PARP Inhibitors in Advanced Ovarian Cancer. (Medscape Oncology)

    • The safety of antiangiogenic agents and PARP inhibitors in platinum-sensitive recurrent ovarian cancer.
    • Lorusso D, Fontanella C, Maltese G, Lepori S, Tripodi E, Bogani G, Raspagliesi F.
    • Expert Opin Drug Saf. 2017 Jun;16(6):687-696. doi: 10.1080/14740338.2017.1325871. Epub 2017 May 18.
    • Review
    • Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer.
    • Hollis RL, Churchman M, Gourley C.
    • Onco Targets Ther. 2017 May 11;10:2539-2551. doi: 10.2147/OTT.S102569. eCollection 2017.
    • Effect of the Combination of Trabectedin and Pegylated Liposomal Doxorubicin in a BRCA2 Mutation Carrier with Recurrent Platinum-Sensitive Ovarian Cancer.
    • Rubio Pérez MJ.
    • Case Rep Oncol. 2017 May 9;10(2):433-437. doi: 10.1159/000475707. eCollection 2017 May-Aug.
    • A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study.
    • Monk BJ, Brady MF, Aghajanian C, Lankes HA, Rizack T, Leach J, Fowler JM, Higgins R, Hanjani P, Morgan M, Edwards R, Bradley W, Kolevska T, Foukas P, Swisher EM, Anderson KS, Gottardo R, Bryan JK, Newkirk M, Manjarrez KL, Mannel RS, Hershberg RM, Coukos G.
    • Ann Oncol. 2017 May 1;28(5):996-1004. doi: 10.1093/annonc/mdx049.
    • Whence High-Grade Serous Ovarian Cancer.
    • Kohn EC, Ivy SP.
    • Am Soc Clin Oncol Educ Book. 2017 May;(37):443-448. doi: 10.1200/EDBK_174718.
    • A paradigm shift in the origin of ovarian cancer: the ovary is no longer to blame.
    • Meyn A, Lim B.
    • BJOG. 2017 May;124(6):859. doi: 10.1111/1471-0528.14609.

    Letter:

    Re: A paradigm shift in the origin of ovarian cancer: the ovary is no longer to blame: Is the ovary to blame for tubal carcinoma?

    • Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials.
    • George A, Kristeleit R, Rafii S, Michie CO, Bowen R, Michalarea V, van Hagen T, Wong M, Rallis G, Molife LR, Lopez J, Banerji U, Banerjee SN, Gore ME, de Bono JS, Kaye SB, Yap TA.
    • Eur J Cancer. 2017 May;76:52-59. doi: 10.1016/j.ejca.2017.01.020. Epub 2017 Mar 6.
    • Ovarian carcinoma histotype in Lynch syndrome.
    • Gilks CB, Clarke BA, Foulkes WD.
    • Gynecol Oncol Rep. 2017 Mar 16;20:140-141. doi: 10.1016/j.gore.2017.03.009. eCollection 2017 May.

    Pathological features and clinical behavior of Lynch syndrome-associated ovarian cancer.

    Letter:

    BRCA and lynch syndrome-associated ovarian cancers behave differently.

    • Prognostic Role of Histological Tumor Regression in Patients Receiving Neoadjuvant Chemotherapy for High-Grade Serous Tubo-ovarian Carcinoma.
    • Coghlan E, Meniawy TM, Munro A, Bulsara M, Stewart CJ, Tan A, Koay ME, MaGee D, Codde J, Tan J, Salfinger SG, Mohan GR, Leung Y, Nichols CB, Cohen PA.
    • Int J Gynecol Cancer. 2017 May;27(4):708-713. doi: 10.1097/IGC.0000000000000945.
    • Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer.
    • Christie EL, Fereday S, Doig K, Pattnaik S, Dawson SJ, Bowtell DDL.
    • J Clin Oncol. 2017 Apr 20;35(12):1274-1280. doi: 10.1200/JCO.2016.70.4627. Epub 2017 Feb 13.
    • Functional and mutational landscapes of BRCA1 for homology-directed repair and therapy resistance.
    • Anantha RW, Simhadri S, Foo TK, Miao S, Liu J, Shen Z, Ganesan S, Xia B.
    • Elife. 2017 Apr 11;6. pii: e21350. doi: 10.7554/eLife.21350.
    • Comparison of Clinical Outcomes of BRCA1/2 Pathologic Mutation, Variants of Unknown Significance, or Wild Type Epithelial Ovarian Cancer Patients.
    • Eoh KJ, Park HS, Park JS, Lee ST, Han J, Lee JY, Kim SW, Kim S, Kim YT, Nam EJ.
    • Cancer Res Treat. 2017 Apr;49(2):408-415. doi: 10.4143/crt.2016.135. Epub 2016 Jul 27.
    • Niraparib for the treatment of ovarian cancer.
    • Kanjanapan Y, Lheureux S, Oza AM.
    • Expert Opin Pharmacother. 2017 Apr;18(6):631-640. doi: 10.1080/14656566.2017.1297423. Epub 2017 Apr 7.
    • Review
    • Possible Compartmental Cytokine Release Syndrome in a Patient With Recurrent Ovarian Cancer After Treatment With Mesothelin-targeted CAR-T Cells.
    • Tanyi JL, Stashwick C, Plesa G, Morgan MA, Porter D, Maus MV, June CH.
    • J Immunother. 2017 Apr;40(3):104-107. doi: 10.1097/CJI.0000000000000160.
    • Case report
    • Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer.
    • Lee JM, Peer CJ, Yu M, Amable L, Gordon N, Annunziata CM, Houston N, Goey AK, Sissung TM, Parker B, Minasian L, Chiou V, Murphy RF, Widemann BC, Figg WD, Kohn EC.
    • Clin Cancer Res. 2017 Mar 15;23(6):1397-1406. doi: 10.1158/1078-0432.CCR-16-1546. Epub 2016 Sep 23.
    • No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival.
    • Sucheston-Campbell LE, Cannioto R, Clay AI, Etter JL, Eng KH, Liu S, Battaglia S, Hu Q, Szender JB, Minlikeeva A, Joseph J, Mayor P, Abrams SI, Segal B, Wallace PK, Soh KT, Zsiros EZ, Anton-Culver H, Bandera EV, Beckmann MW, Berchuck A, Bjørge L, Bruegl A, Campbell IG, Campbell SP, Chenevix-Trench G, Cramer D, Dansonka-Mieszkowska A, Dao F, Diergaarde B, Doerk T, Doherty JA, du Bois A, Eccles D, Engelholm SA, Fasching PA, Gayther SA, Gentry-Maharaj A, Glasspool RM, Goodman MT, Gronwald J, Harter P, Hein A, Heitz F, Hillemmanns P, Hogdall C, Høgdall EV, Huzarski T, Jensen A, Johnatty SE, Jung A, Karlan B, Klapdor R, Kluz T, Konopka B, Krüger Kjær S, Kupryjanczyk J, Lambrechts D, Lester J, Lubiński J, Levine DA, Lundvall L, McGuire V, McNeish IA, Menon U, Modugno F, Ness RB, Orsulic S, Paul J, Pearce CL, Pejovic T, Pharoah P, Ramus SJ, Rothstein J, Rossing MA, Rübner M, Schildkraut JM, Schmalfeldt B, Schwaab I, Siddiqui N, Sieh W, Sobiczewski P, Song H, Terry KL, Van Nieuwenhuysen E, Vanderstichele A, Vergote I, Walsh CS, Webb PM, Wentzensen N, Whittemore AS, Wu AH, Ziogas A, Odunsi K, Chang-Claude J, Goode EL, Moysich KB.
    • Cancer Epidemiol Biomarkers Prev. 2017 Mar;26(3):420-424. doi: 10.1158/1055-9965.EPI-16-0631. Epub 2016 Sep 27.
    • Pathological features and clinical behavior of Lynch syndrome-associated ovarian cancer.
    • Ryan NA, Evans DG, Green K, Crosbie EJ.
    • Gynecol Oncol. 2017 Mar;144(3):491-495. doi: 10.1016/j.ygyno.2017.01.005. Epub 2017 Jan 6.

    Letter: Ovarian carcinoma histotype in Lynch syndrome. (Gynecologic Oncology Reports)

    Letter:

    BRCA and lynch syndrome-associated ovarian cancers behave differently.

    • The Prognostic Value of BRCA1 and PARP Expression in Epithelial Ovarian Carcinoma: Immunohistochemical Detection.
    • Hjortkjær M, Waldstrøm M, Jakobsen A, Kanstrup H, Søgaard-Andersen E, Dahl Steffensen K.
    • Int J Gynecol Pathol. 2017 Mar;36(2):180-189. doi: 10.1097/PGP.0000000000000310.
    • Analysis of chromosomal radiosensitivity of healthy BRCA2 mutation carriers and non-carriers in BRCA families with the G2 micronucleus assay.
    • Baert A, Depuydt J, Van Maerken T, Poppe B, Malfait F, Van Damme T, De Nobele S, Perletti G, De Leeneer K, Claes KB, Vral A.
    • Oncol Rep. 2017 Mar;37(3):1379-1386. doi: 10.3892/or.2017.5407. Epub 2017 Jan 25.
    • Differences in survival for patients with familial and sporadic cancer.
    • Lee M, Reilly M, Lindström LS, Czene K.
    • Int J Cancer. 2017 Feb 1;140(3):581-590. doi: 10.1002/ijc.30476. Epub 2016 Nov 3.
    • Prognosis of patients with BRCA1-associated ovarian carcinomas depends on TP53 accumulation status in tumor cells.
    • Rzepecka IK, Szafron LM, Stys A, Felisiak-Golabek A, Podgorska A, Timorek A, Sobiczewski P, Pienkowska-Grela B, El-Bahrawy M, Kupryjanczyk J.
    • Gynecol Oncol. 2017 Feb;144(2):369-376. doi: 10.1016/j.ygyno.2016.11.028. Epub 2016 Dec 7.
    • [Clinical-based study of ovarian cancer patients with and without BRCA1/2 genes mutation: clinical features and pedigree analysis].
    • Tao T, Yang JX, Shen K, Cao DY.
    • Zhonghua Fu Chan Ke Za Zhi. 2017 Jan 25;52(1):20-25. doi: 10.3760/cma.j.issn.0529-567X.2017.01.006.
    • Article in Chinese; English Abstract
    • [Clinical significance and distribution of BRCA genes mutation in sporadic high grade serous ovarian cancer].
    • Liu WL, Wang ZZ, Zhao JZ, Hou YY, Wu XX, Li W, Dong B, Tong TT, Guo YJ.
    • Zhonghua Fu Chan Ke Za Zhi. 2017 Jan 25;52(1):26-31. doi: 10.3760/cma.j.issn.0529-567X.2017.01.007.
    • Article in Chinese; English Abstract
    • Prognostic significance of BRCA mutations in ovarian cancer: an updated systematic review with meta-analysis.
    • Xu K, Yang S, Zhao Y.
    • Oncotarget. 2017 Jan 3;8(1):285-302. doi: 10.18632/oncotarget.12306.
    • Genomic LOH May Predict Rucaparib Response in Ovarian Cancer.
    • [No authors listed]
    • Cancer Discov. 2017 Jan;7(1):OF8. doi: 10.1158/2159-8290.CD-RW2016-230. Epub 2016 Dec 9.
    • Research News
    • Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
    • Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, Konecny GE, Coleman RL, Tinker AV, O'Malley DM, Kristeleit RS, Ma L, Bell-McGuinn KM, Brenton JD, Cragun JM, Oaknin A, Ray-Coquard I, Harrell MI, Mann E, Kaufmann SH, Floquet A, Leary A, Harding TC, Goble S, Maloney L, Isaacson J, Allen AR, Rolfe L, Yelensky R, Raponi M, McNeish IA.
    • Lancet Oncol. 2017 Jan;18(1):75-87. doi: 10.1016/S1470-2045(16)30559-9. Epub 2016 Nov 29.

    Comment:

    Progress in PARP inhibitors beyond BRCA mutant recurrent ovarian cancer?

    • Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    • Tappenden P, Harnan S, Ren S, Thokala P, Wong R, Mukuria C, Green C, Pledge S, Tidy J.
    • Pharmacoeconomics. 2017 Jan;35(1):97-109. doi: 10.1007/s40273-016-0440-x.
    • Olaparib (LYNPARZAO) Ovarian cancer: spare patients who are in remission.
    • [No authors listed]
    • Prescrire Int. 2017 Jan;26(178):9-12.
    • Germ line mutations associated with leukemias.
    • Porter CC.
    • Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):302-308.
    • Review
    • Do Ovarian Cancer Patients with a Family History of Cancer (Suspected BRCA1 or BRCA2 Mutation) Suffer Greater Chemotherapy Toxicity?
    • Egloff H, Jatoi A.
    • Cancer Invest. 2016 Nov 25;34(10):531-535. Epub 2016 Oct 28.
    • Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer.
    • Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Bennett B, Parry D, Spencer S, Mann H, Matulonis U.
    • Br J Cancer. 2016 Nov 22;115(11):1313-1320. doi: 10.1038/bjc.2016.348. Epub 2016 Nov 8.
    • Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers.
    • Zaaijer LH, van Doorn HC, Mourits MJ, van Beurden M, de Hullu JA, Adank MA, van Lonkhuijzen LR, Vasen HF, Slangen BF, Gaarenstroom KN, Zweemer RP, Vencken PM, Seynaeve C, Kriege M.
    • Br J Cancer. 2016 Nov 8;115(10):1174-1178. doi: 10.1038/bjc.2016.333. Epub 2016 Oct 18.
    • A BRCA1/2 Mutational Signature and Survival in Ovarian High-Grade Serous Carcinoma.
    • Dong F, Davineni PK, Howitt BE, Beck AH.
    • Cancer Epidemiol Biomarkers Prev. 2016 Nov;25(11):1511-1516. Epub 2016 Aug 5.
    • Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
    • Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Rowe P, Lowe E, Hodgson D, Sovak MA, Matulonis U.
    • Lancet Oncol. 2016 Nov;17(11):1579-1589. doi: 10.1016/S1470-2045(16)30376-X. Epub 2016 Sep 9.
    • Beside P53 and PTEN: Identification of molecular alterations of the RAS/MAPK and PI3K/AKT signaling pathways in high-grade serous ovarian carcinomas to determine potential novel therapeutic targets.
    • Chen S, Cavazza E, Barlier C, Salleron J, Filhine-Tresarrieu P, Gavoilles C, Merlin JL, Harlé A.
    • Oncol Lett. 2016 Nov;12(5):3264-3272. Epub 2016 Sep 2.
    • Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study.
    • Pulford DJ, Harter P, Floquet A, Barrett C, Suh DH, Friedlander M, Arranz JA, Hasegawa K, Tada H, Vuylsteke P, Mirza MR, Donadello N, Scambia G, Johnson T, Cox C, Chan JK, Imhof M, Herzog TJ, Calvert P, Wimberger P, Berton-Rigaud D, Lim MC, Elser G, Xu CF, du Bois A.
    • BMC Med Ethics. 2016 Oct 21;17(1):63.
    • Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis.
    • Sabatier R, Lavit E, Moretta J, Lambaudie E, Noguchi T, Eisinger F, Cherau E, Provansal M, Livon D, Rabayrol L, Popovici C, Charaffe-Jauffret E, Sobol H, Viens P.
    • Fam Cancer. 2016 Oct;15(4):497-506. doi: 10.1007/s10689-016-9873-9.
    • Sequence-specific pharmacokinetic and pharmacodynamic phase I/Ib study of olaparib tablets and carboplatin in women's cancer.
    • Lee JM, Peer CJ, Yu M, Amable L, Gordon N, Annunziata CM, Houston N, Goey AK, Sissung TM, Parker B, Minasian L, Chiou V, Murphy RF, Widemann BC, Figg WD, Kohn EC.
    • Clin Cancer Res. 2016 Sep 23. pii: clincanres.1546.2016. [Epub ahead of print]
    • Prognostic implications of reproductive and lifestyle factors in ovarian cancer.
    • Poole EM, Konstantinopoulos PA, Terry KL.
    • Gynecol Oncol. 2016 Sep;142(3):574-87. doi: 10.1016/j.ygyno.2016.05.014. Epub 2016 May 29.
    • Review
    • Germline mutations of BRCA1 gene exon 11 are not associated with platinum response neither with survival advantage in patients with primary ovarian cancer: understanding the clinical importance of one of the biggest human exons. A study of the Tumor Bank Ovarian Cancer (TOC) Consortium.
    • Dimitrova D, Ruscito I, Olek S, Richter , Hellwag A, Türbachova I, Woopen H, Baron U, Braicu EI, Sehouli J.
    • Tumour Biol. 2016 Sep;37(9):12329-12337. doi: 10.1007/s13277-016-5109-8. Epub 2016 Jun 14.
    • Single-sample expression-based chemo-sensitivity score improves survival associations independently from genomic mutations for ovarian cancer Patients.
    • Zimmermann MT, Jiang G, Wang C.
    • AMIA Jt Summits Transl Sci Proc. 2016 Jul 20;2016:94-100. eCollection 2016.
    • Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy.
    • Matulonis UA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Parry D, Grinsted L, Ledermann JA.
    • Cancer. 2016 Jun 15;122(12):1844-52. doi: 10.1002/cncr.29995. Epub 2016 Apr 8.
    • The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type.
    • Witkowski L, Goudie C, Ramos P, Boshari T, Brunet JS, Karnezis AN, Longy M, Knost JA, Saloustros E, McCluggage WG, Stewart CJ, Hendricks WP, Cunliffe H, Huntsman DG, Pautier P, Levine DA, Trent JM, Berchuck A, Hasselblatt M, Foulkes WD.
    • Gynecol Oncol. 2016 Jun;141(3):454-60. doi: 10.1016/j.ygyno.2016.03.013. Epub 2016 Mar 19.
    • Ovarian cancer in BRCA1 and BRCA2 gene mutation carriers: analysis of prognostic factors and survival.
    • Biglia N, Sgandurra P, Bounous VE, Maggiorotto F, Piva E, Pivetta E, Ponzone R, Pasini B.
    • Ecancermedicalscience. 2016 May 3;10:639. doi: 10.3332/ecancer.2016.639. eCollection 2016.
    • Characteristics of 10-year survivors of high-grade serous ovarian carcinoma.
    • Dao F, Schlappe BA, Tseng J, Lester J, Nick AM, Lutgendorf SK, McMeekin S, Coleman RL, Moore KN, Karlan BY, Sood AK, Levine DA.
    • Gynecol Oncol. 2016 May;141(2):260-3. doi: 10.1016/j.ygyno.2016.03.010. Epub 2016 Mar 11.
    • Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer.
    • Zhang M, Liu G, Xue F, Edwards R, Sood AK, Zhang W, Yang D.
    • Gynecol Oncol. 2016 Apr;141(1):57-64. doi: 10.1016/j.ygyno.2016.01.004.
    • BRCA testing, treatment patterns and survival in platinum-sensitive recurrent ovarian cancer - an observational cohort study.
    • Unni SK, Schauerhamer MB, Deka R, Tyczynski JE, Fernandes AW, Stevens V, Brixner DI, Stenehjem DD.
    • J Ovarian Res. 2016 Mar 22;9(1):18. doi: 10.1186/s13048-016-0227-x.
    • Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
    • Strickland KC, Howitt BE, Shukla SA, Rodig S, Ritterhouse LL, Liu JF, Garber JE, Chowdhury D, Wu CJ, D'Andrea AD, Matulonis UA, Konstantinopoulos PA.
    • Oncotarget. 2016 Mar 22;7(12):13587-98. doi: 10.18632/oncotarget.7277.
    • Effect of the BRCA1-SIRT1-EGFR axis on cisplatin sensitivity in ovarian cancer.
    • Li D, Wu QJ, Bi FF, Chen SL, Zhou YM, Zhao Y, Yang Q.
    • Am J Transl Res. 2016 Mar 15;8(3):1601-8. eCollection 2016.
    • Invasion Patterns of Metastatic Extrauterine High-grade Serous Carcinoma With BRCA Germline Mutation and Correlation With Clinical Outcomes.
    • Hussein YR, Ducie JA, Arnold AG, Kauff ND, Vargas-Alvarez HA, Sala E, Levine DA, Soslow RA.
    • Am J Surg Pathol. 2016 Mar;40(3):404-9. doi: 10.1097/PAS.0000000000000556.
    • Breast-conserving Therapy and the Risk of Second Primaries in BRCA1/2 Mutation Carriers.
    • Hallam S, Govindarajulu S, Huckett R, Bahl A.
    • Clin Oncol (R Coll Radiol). 2016 Mar;28(3):225. doi: 10.1016/j.clon.2015.11.012. Epub 2015 Dec 19.
    • Comment, Letter

    Response / Letter

    Is Breast-conserving Therapy Really a Good Option for BRCA1/2 Mutation Carriers?

    • BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.
    • Harter P, Johnson T, Berton-Rigaud D, Park SY, Friedlander M, Del Campo JM, Shimada M, Forget F, Mirza MR, Colombo N, Zamagni C, Chan JK, Imhof M, Herzog TJ, O'Donnell D, Heitz F, King K, Stinnett S, Barrett C, Jobanputra M, Xu CF, du Bois A.
    • Gynecol Oncol. 2016 Mar;140(3):443-9. doi: 10.1016/j.ygyno.2015.12.027. Epub 2015 Dec 29.
    • BRCA2-positive spinal intramedullary ovarian metastatic disease: case report.
    • Ravindra VM, Mazur MD, Driscoll M, McEvoy S, Schmidt MH.
    • Spine J. 2016 Mar;16(3):e201-7. doi: 10.1016/j.spinee.2015.10.053. Epub 2015 Nov 10.
    • Case report
    • Prognostic factors in Polish patients with BRCA1-dependent ovarian cancer.
    • Szatkowski W, Blecharz P, Mituś JW, Jasiówka M, Łuczyńska E, Jakubowicz J, Byrski T.
    • Hered Cancer Clin Pract. 2016 Jan 23;14:4. doi: 10.1186/s13053-015-0041-2. eCollection 2016.
    • Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status.
    • Kotsopoulos J, Rosen B, Fan I, Moody J, McLaughlin JR, Risch H, May T, Sun P, Narod SA.
    • Gynecol Oncol. 2016 Jan;140(1):42-47. doi: 10.1016/j.ygyno.2015.11.009. Epub 2015 Nov 7.
    • Treatment related toxicity in BRCA1-associated epithelial ovarian cancer - is DNA repairing impairment associated with more adverse events?
    • Badora-Rybicka A, Budryk M, Nowara E, Starzyczny-Słota D.
    • Contemp Oncol (Pozn). 2016;20(5):381-384. doi: 10.5114/wo.2016.64597. Epub 2016 Dec 20.
    • Comparison of effectiveness of treatment of patients with sporadic and germline BRCA1-related ovarian cancer.
    • Szatkowski W, Muzykiewicz K, Jasiówka M, Karolewski K, Kojs Z, Klimek M, Blecharz P.
    • Ginekol Pol. 2016;87(6):422-5. doi: 10.5603/GP.2016.0019.
    • Clinical outcomes in patients with isolated serous tubal intraepithelial carcinoma (STIC): A comprehensive review.
    • Patrono MG, Iniesta MD, Malpica A, Lu KH, Fernandez RO, Salvo G, Ramirez PT.
    • Gynecol Oncol. 2015 Dec;139(3):568-572. doi: 10.1016/j.ygyno.2015.09.018. Epub 2015 Sep 25.
    • Review
    • Epithelial Ovarian Cancer Metastatic to the Central Nervous System and a Family History Concerning for Hereditary Breast and Ovarian Cancer--A Potential Relationship.
    • Jernigan AM, Mahdi H, Rose PG.
    • Int J Gynecol Cancer. 2015 Sep;25(7):1232-8. doi: 10.1097/IGC.0000000000000489.
    • A Single Nucleotide Polymorphism in Catalase Is Strongly Associated with Ovarian Cancer Survival.
    • Belotte J, Fletcher NM, Saed MG, Abusamaan MS, Dyson G, Diamond MP, Saed GM.
    • PLoS One. 2015 Aug 24;10(8):e0135739. doi: 10.1371/journal.pone.0135739. eCollection 2015.
    • Effects of BRCA1/2 on Ovarian and Breast Cancer Survival-Letter.
    • Gong L, Dong C, Ouyang W.
    • Clin Cancer Res. 2015 Aug 15;21(16):3806. doi: 10.1158/1078-0432.CCR-15-0418.
    • Comment, Letter

    Meta-Analysis

    Effects of BRCA1- and BRCA2-Related Mutations on Ovarian and Breast Cancer Survival: A Meta-analysis.

    Letter

    Effects of BRCA1/2 on Ovarian and Breast Cancer Survival-Response.

    • Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
    • Liu Y, Yasukawa M, Chen K, Hu L, Broaddus RR, Ding L, Mardis ER, Spellman P, Levine DA, Mills GB, Shmulevich I, Sood AK, Zhang W.
    • JAMA Oncol. 2015 Jul 1;1(4):486-494. doi: 10.1001/jamaoncol.2015.1432.

    Comment

    Gynaecological cancer: ADAMTS mutations predict sensitivity to chemotherapy in ovarian cancer.

    • Effect of Breast Cancer After Ovarian Cancer on Mortality for BRCA Mutation Carriers.
    • Liede A, Sun P, Narod S.
    • JAMA Surg. 2015 May 1;150(5):490-491. doi: 10.1001/jamasurg.2015.0193.
    • Comment, Letter

    Breast Cancer Following Ovarian Cancer in BRCA Mutation Carriers.

    Letter

    Effect of Breast Cancer After Ovarian Cancer on Mortality for BRCA Mutation Carriers-Reply.

    • Clinical characteristics and outcomes of patients with stage I epithelial ovarian cancer compared with fallopian tube cancer.
    • Rauh-Hain JA, Foley OW, Winograd D, Andrade C, Clark RM, Vargas RJ, Hinchcliff EM, Esselen KM, Horowitz NS, del Carmen MG.
    • Am J Obstet Gynecol. 2015 May;212(5):600.e1-8. doi: 10.1016/j.ajog.2014.12.013. Epub 2014 Dec 13.
    • Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study†.
    • Monk BJ, Ghatage P, Parekh T, Henitz E, Knoblauch R, Matos-Pita AS, Nieto A, Park YC, Cheng PS, Li W, Favis R, Ricci D, Poveda A.
    • Ann Oncol. 2015 May;26(5):914-20. doi: 10.1093/annonc/mdv071. Epub 2015 Feb 26.
    • Ovarian cancer survival by tumor dominance, a surrogate for site of origin.
    • Ivanova A, Loo A, Tworoger S, Crum CP, Fan I, McLaughlin JR, Rosen B, Risch H, Narod SA, Kotsopoulos J.
    • Cancer Causes Control. 2015 Apr;26(4):601-8. doi: 10.1007/s10552-015-0547-y. Epub 2015 Mar 13.
    • Serous ovarian, fallopian tube and primary peritoneal cancers: A common disease or separate entities - A systematic review.
    • Sørensen RD, Schnack TH, Karlsen MA, Høgdall CK.
    • Gynecol Oncol. 2015 Mar;136(3):571-581. doi: 10.1016/j.ygyno.2015.01.534. Epub 2015 Jan 20.
    • Review
    • Serous Tubal Intraepithelial Carcinoma Localizes to the Tubal-peritoneal Junction: A Pivotal Clue to the Site of Origin of Extrauterine High-grade Serous Carcinoma (Ovarian Cancer).
    • Seidman JD.
    • Int J Gynecol Pathol. 2015 Mar;34(2):112-20. doi: 10.1097/PGP.0000000000000123.
    • Germline Mutation in BRCA1 or BRCA2 and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian Cancer.
    • Candido-dos-Reis FJ, Song H, Goode EL, Cunningham JM, Fridley BL, Larson MC, Alsop K, Dicks E, Harrington P, Ramus SJ, de Fazio A, Mitchell G, Fereday S, Bolton KL, Gourley C, Michie C, Karlan B, Lester J, Walsh C, Cass I, Olsson H, Gore M, Benitez JJ, Garcia MJ, Andrulis I, Mulligan AM, Glendon G, Blanco I, Lazaro C, Whittemore AS, McGuire V, Sieh W, Montagna M, Alducci E, Sadetzki S, Chetrit A, Kwong A, Kjaer SK, Jensen A, Høgdall E, Neuhausen S, Nussbaum R, Daly M, Greene MH, Mai PL, Loud JT, Moysich K, Toland AE, Lambrechts D, Ellis S, Frost D, Brenton JD, Tischkowitz M, Easton DF, Antoniou A, Chenevix-Trench G, Gayther SA, Bowtell D, Pharoah PD; for EMBRACE; kConFab Investigators; Australian Ovarian Cancer Study Group.
    • Clin Cancer Res. 2015 Feb 1;21(3):652-7. doi: 10.1158/1078-0432.CCR-14-2497. Epub 2014 Nov 14.
    • DNA repair mutations and outcomes in ovarian cancer--letter.
    • Soslow RA.
    • Clin Cancer Res. 2015 Feb 1;21(3):658. doi: 10.1158/1078-0432.CCR-14-2436.

    Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.

    Comment / Letter

    DNA repair mutations and outcomes in ovarian cancer--response.

    • Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy.
    • Tecza K, Pamula-Pilat J, Kolosza Z, Radlak N, Grzybowska E.
    • J Exp Clin Cancer Res. 2015 Jan 16;34:2. doi: 10.1186/s13046-015-0124-y.
    • Effects of BRCA1- and BRCA2-Related Mutations on Ovarian and Breast Cancer Survival: A Meta-analysis.
    • Zhong Q, Peng HL, Zhao X, Zhang L, Hwang WT.
    • Clin Cancer Res. 2015 Jan 1;21(1):211-20. doi: 10.1158/1078-0432.CCR-14-1816. Epub 2014 Oct 27.

    Comment / Letter

    Effects of BRCA1/2 on Ovarian and Breast Cancer Survival-Letter.

    Reply / Letter

    Effects of BRCA1/2 on Ovarian and Breast Cancer Survival-Response.

    • Breast Cancer Following Ovarian Cancer in BRCA Mutation Carriers.
    • Gangi A, Cass I, Paik D, Barmparas G, Karlan B, Dang C, Li A, Walsh C, Rimel BJ, Amersi FF.
    • JAMA Surg. 2014 Dec 1;149(12):1306-1313. doi: 10.1001/jamasurg.2014.1081.

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: Breast cancer risk in ovarian cancer survivors

    Subject: BRCA+ ovarian ca dx- breast ca risk and outcomes

    Letter

    Effect of Breast Cancer After Ovarian Cancer on Mortality for BRCA Mutation Carriers.

    Letter, Reply

    Effect of Breast Cancer After Ovarian Cancer on Mortality for BRCA Mutation Carriers-Reply.

    • BRCA1/2 Mutation Status Is an Independent Factor of Improved Survival for Advanced (Stage III-IV) Ovarian Cancer.
    • Rudaitis V, Zvirblis T, Kanopiene D, Janulynaite D, Griskevicius L, Janavicius R.
    • Int J Gynecol Cancer. 2014 Oct;24(8):1395-400. doi: 10.1097/IGC.0000000000000247.
    • Invasion patterns of metastatic high-grade serous carcinoma of ovary or fallopian tube associated with BRCA deficiency.
    • Reyes MC, Arnold AG, Kauff ND, Levine DA, Soslow RA.
    • Mod Pathol. 2014 Oct;27(10):1405-11. doi: 10.1038/modpathol.2013.237. Epub 2014 Feb 28.
    • BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients - A study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD).
    • Ruscito I, Dimitrova D, Vasconcelos I, Gellhaus K, Schwachula T, Bellati F, Zeillinger R, Benedetti-Panici P, Vergote I, Mahner S, Cacsire-Tong D, Concin N, Darb-Esfahani S, Lambrechts S, Sehouli J, Olek S, Braicu EI.
    • Eur J Cancer. 2014 Aug;50(12):2090-8. doi: 10.1016/j.ejca.2014.05.001. Epub 2014 Jun 2.
    • Impact of Oophorectomy on Cancer Incidence and Mortality in Women With a BRCA1 or BRCA2 Mutation.
    • Finch AP, Lubinski J, Møller P, Singer CF, Karlan B, Senter L, Rosen B, Maehle L, Ghadirian P, Cybulski C, Huzarski T, Eisen A, Foulkes WD, Kim-Sing C, Ainsworth P, Tung N, Lynch HT, Neuhausen S, Metcalfe KA, Thompson I, Murphy J, Sun P, Narod SA.
    • J Clin Oncol. 2014 May 20;32(15):1547-53. doi: 10.1200/JCO.2013.53.2820. Epub 2014 Feb 24.

    Comment, Editorial:

    A major step forward for BRCA1/2-related cancer risk management.

    Research news: Oophorectomy in women with BRCA1 or BRCA2 mutations. (Lancet Oncology)

    Press: Early Surgery in BRCA1 Carriers Lowers Ovarian Cancer Risk. (Medscape)

    Press: Young women with BRCA1 mutation 'should remove ovaries earlier'. (Medical News Today)

    • The Role of BRCA Status on the Prognosis of Patients with Epithelial Ovarian Cancer: A Systematic Review of the Literature with a Meta-Analysis.
    • Sun C, Li N, Ding D, Weng D, Meng L, Chen G, Ma D.
    • PLoS One. 2014 May 1;9(5):e95285. doi: 10.1371/journal.pone.0095285. eCollection 2014.
    • Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.
    • Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, Thornton A, Norquist BM, Casadei S, Nord AS, Agnew KJ, Pritchard CC, Scroggins S, Garcia RL, King MC, Swisher EM.
    • Clin Cancer Res. 2014 Feb 1;20(3):764-75. doi: 10.1158/1078-0432.CCR-13-2287. Epub 2013 Nov 15.

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: PALB2 and Ovarian Cancer

    Comment, Letter

    DNA repair mutations and outcomes in ovarian cancer--letter.

    Reply, Letter

    DNA repair mutations and outcomes in ovarian cancer--response.

    • Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations.
    • Birkbak NJ, Kochupurakkal B, Izarzugaza JM, Eklund AC, Li Y, Liu J, Szallasi Z, Matulonis UA, Richardson AL, Iglehart JD, Wang ZC.
    • PLoS One. 2013 Nov 12;8(11):e80023. doi: 10.1371/journal.pone.0080023. eCollection 2013.
    • BRCA mutations and outcome in epithelial ovarian cancer (EOC): experience in ethnically diverse groups.
    • Safra T, Lai WC, Borgato L, Nicoletto MO, Berman T, Reich E, Alvear M, Haviv I, Muggia FM.
    • Ann Oncol. 2013 Nov;24 Suppl 8:viii63-viii68. doi: 10.1093/annonc/mdt315.
    • Clinical Outcome of Isolated Serous Tubal Intraepithelial Carcinomas (STIC).
    • Wethington SL, Park KJ, Soslow RA, Kauff ND, Brown CL, Dao F, Otegbeye E, Sonoda Y, Abu-Rustum NR, Barakat RR, Levine DA, Gardner GJ.
    • Int J Gynecol Cancer. 2013 Nov;23(9):1603-11. doi: 10.1097/IGC.0b013e3182a80ac8.
    • Added value of family history in counseling about risk of BRCA1/2 mutation in early-onset epithelial ovarian cancer.
    • Arts-de Jong M, Manders CM, Hoogerbrugge N, Ligtenberg MJ, Massuger LF, de Hullu JA, Spruijt L.
    • Int J Gynecol Cancer. 2013 Oct;23(8):1406-10. doi: 10.1097/IGC.0b013e3182a1cf71.
    • [Characteristics of selected clinical features in BRCA1 mutation carriers affected with breast cancer undergoing preventive female genital tract surgeries].
    • Menkiszak J, Chudecka-Głaz A, Gronwald J, Bedner R, Cymbaluk-Płoska A, Wezowska M, Zielińska D, Rzepka-Górska I.
    • Ginekol Pol. 2013 Sep;84(9):758-64.
    • Predicting time to ovarian carcinoma recurrence using protein markers.
    • Yang JY, Yoshihara K, Tanaka K, Hatae M, Masuzaki H, Itamochi H; Cancer Genome Atlas (TCGA) Research Network, Takano M, Ushijima K, Tanyi JL, Coukos G, Lu Y, Mills GB, Verhaak RG.
    • J Clin Invest. 2013 Sep;123(9):3740-50. doi: 10.1172/JCI68509. Epub 2013 Aug 15.

    Erratum: Predicting time to ovarian carcinoma recurrence using protein markers (Journal of Clinical Investigation)

    • Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions.
    • Moon DH, Lee JM, Noonan AM, Annunziata CM, Minasian L, Houston N, Hays JL, Kohn EC.
    • Br J Cancer. 2013 Aug 20;109(4):1072-8. doi: 10.1038/bjc.2013.389. Epub 2013 Jul 18.
    • Assessment of the Prognostic Value of Two Common Variants of BRCA1 and BRCA2 Genes in Ovarian Cancer Patients Treated with Cisplatin and Paclitaxel: A Gynecologic Oncology Group Study.
    • Tian CQ, Darcy KM, Krivak TC, Deloia JA, Armstrong D, Davis W, Zhao H, Moysich K, Ambrosone CB.
    • Front Oncol. 2013 Aug 12;3:206. doi: 10.3389/fonc.2013.00206. eCollection 2013.
    • Outcome of BRCA1- compared with BRCA2-associated ovarian cancer: a nationwide study in the Netherlands.
    • Vencken PM, Reitsma W, Kriege M, Mourits MJ, de Bock GH, de Hullu JA, van Altena AM, Gaarenstroom KN, Vasen HF, Adank MA, Schmidt MK, van Beurden M, Zweemer RP, Rijcken F, Slangen BF, Burger CW, Seynaeve C.
    • Ann Oncol. 2013 Aug;24(8):2036-42. doi: 10.1093/annonc/mdt068. Epub 2013 Mar 29.
    • The different impact of BRCA mutations on the survival of epithelial ovarian cancer patients: a retrospective single-center experience.
    • Lorusso D, Cirillo F, Mancini M, Spatti GB, Grijuela B, Ditto A, Raspagliesi F.
    • Oncology. [2013 Aug;]85(2):122-7. doi: 10.1159/000353786. Epub 2013 Aug 13.
    • Do deeper sections increase the frequency of detection of serous tubal intraepithelial carcinoma (STIC) in the "sectioning and extensively examining the FIMbriated end" (SEE-FIM) protocol?
    • Mahe E, Tang S, Deb P, Sur M, Lytwyn A, Daya D.
    • Int J Gynecol Pathol. 2013 Jul;32(4):353-7. doi: 10.1097/PGP.0b013e318264ae09.
    • BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study.
    • Lesnock JL, Darcy KM, Tian C, Deloia JA, Thrall MM, Zahn C, Armstrong DK, Birrer MJ, Krivak TC.
    • Br J Cancer. 2013 Apr 2;108(6):1231-7. doi: 10.1038/bjc.2013.70. Epub 2013 Mar 5.

    Research news: Can BRCA Expression Predict Response to Chemotherapy? (Medscape)

    • Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer.
    • Domchek SM, Jhaveri K, Patil S, Stopfer JE, Hudis C, Powers J, Stadler Z, Goldstein L, Kauff N, Khasraw M, Offit K, Nathanson KL, Robson M.
    • Cancer. 2013 Apr 1;119(7):1344-1348. doi: 10.1002/cncr.27842. Epub 2012 Nov 16.

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: Breast cancer risk in ovarian cancer survivors

    Subject: BRCA+ ovarian ca dx- breast ca risk and outcomes

    • BRCA1: A Missing Link in the Fanconi Anemia/BRCA Pathway.
    • D'Andrea AD.
    • Cancer Discov. 2013 Apr;3(4):376-8. doi: 10.1158/2159-8290.CD-13-0044.

    Case report:

    Biallelic deleterious BRCA1 mutations in a woman with early-onset ovarian cancer.

    • Biallelic deleterious BRCA1 mutations in a woman with early-onset ovarian cancer.
    • Domchek SM1, Tang J, Stopfer J, Lilli DR, Hamel N, Tischkowitz M, Monteiro AN, Messick TE, Powers J, Yonker A, Couch FJ, Goldgar DE, Davidson HR, Nathanson KL, Foulkes WD, Greenberg RA.
    • Cancer Discov. 2013 Apr;3(4):399-405. doi: 10.1158/2159-8290.CD-12-0421. Epub 2012 Dec 26.

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: BRCA1 deleterious mutation plus VUS on exon 9

    Commentary

    BRCA1: A Missing Link in the Fanconi Anemia/BRCA Pathway.

    • Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer.
    • Tan DS, Yap TA, Hutka M, Roxburgh P, Ang J, Banerjee S, Grzybowska E, Gourley C, Gore ME, Kaye SB.
    • Eur J Cancer. 2013 Apr;49(6):1246-53. doi: 10.1016/j.ejca.2012.11.016. Epub 2012 Dec 19.
    • The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers: Implications for counseling.
    • Vencken PM, Kriege M, Hooning M, Menke-Pluymers MB, Heemskerk-Gerritsen BA, van Doorn LC, Collée MM, Jager A, van Montfort C, Burger CW, Seynaeve C.
    • Cancer. 2013 Mar 1;119(5):955-62. doi: 10.1002/cncr.27839. Epub 2012 Nov 16.

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: Breast cancer risk in ovarian cancer survivors

    Subject: BRCA+ ovarian ca dx- breast ca risk and outcomes

    • Estimating survival rates after ovarian cancer among women tested for BRCA1 and BRCA2 mutations.
    • Narod S, Moody J, Rosen B, Fan I, Risch A, Sun P, McLaughlin J.
    • Clin Genet. 2013 Mar;83(3):232-237. doi: 10.1111/j.1399-0004.2012.01906.x. Epub 2012 Jul 3.
    • Characteristics of women with ovarian carcinoma who have BRCA1 and BRCA2 mutations not identified by clinical testing.
    • Norquist BM, Pennington KP, Agnew KJ, Harrell MI, Pennil CC, Lee MK, Casadei S, Thornton AM, Garcia RL, Walsh T, Swisher EM.
    • Gynecol Oncol. 2013 Mar;128(3):483-7. doi: 10.1016/j.ygyno.2012.12.015. Epub 2012 Dec 19.
    • 53BP1 expression in sporadic and inherited ovarian carcinoma: Relationship to genetic status and clinical outcomes.
    • Pennington KP, Wickramanayake A, Norquist BM, Pennil CC, Garcia RL, Agnew KJ, Taniguchi T, Welcsh P, Swisher EM.
    • Gynecol Oncol. 2013 Mar;128(3):493-9. doi: 10.1016/j.ygyno.2012.12.007. Epub 2012 Dec 12.
    • Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2.
    • McLaughlin JR, Rosen B, Moody J, Pal T, Fan I, Shaw PA, Risch HA, Sellers TA, Sun P, Narod SA.
    • J Natl Cancer Inst. 2013 Jan 16;105(2):141-8. doi: 10.1093/jnci/djs494. Epub 2012 Dec 20.

    Free Medscape-style version: Long-Term Ovarian Cancer Survival Associated With Mutation in BRCA1 or BRCA2 (Medscape)

    • Phenotypic characterization of hereditary epithelial ovarian cancer based on a tissue microarray study.
    • Muñoz-Repeto I, García MJ, Kamieniak M, Ramón Y Cajal T, Domingo S, Cazorla A, García Donas J, Hernando Polo S, García Sagredo JM, Hernández E, Lacambra C, Saez R, Robles L, Borrego S, Prat J, Palacios J, Benítez J.
    • Histol Histopathol. 2013 Jan;28(1):133-44.
    • Survival prediction based on inherited gene variation analysis.
    • Cicek MS, Maurer MJ, Goode EL.
    • Methods Mol Biol. 2013;1049:53-64. doi: 10.1007/978-1-62703-547-7_5.
    • BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer.
    • Stefansson OA, Villanueva A, Vidal A, Martí L, Esteller M.
    • Epigenetics. 2012 Nov;7(11):1225-9. doi: 10.4161/epi.22561. Epub 2012 Oct 15.
    • [Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer].
    • Bremer M.
    • Strahlenther Onkol. 2012 Nov;188(11):1057-8. doi: 10.1007/s00066-012-0219-8.
    • Comment, [Article in German]

    Meta-Analysis:

    Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.

    • Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer.
    • Liu G, Yang D, Sun Y, Shmulevich I, Xue F, Sood AK, Zhang W.
    • Pharmacogenomics. 2012 Oct;13(13):1523-35. doi: 10.2217/pgs.12.137.

    Press: Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer. (Medscape)

    • Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer.
    • Hyman DM, Zhou Q, Iasonos A, Grisham RN, Arnold AG, Phillips MF, Bhatia J, Levine DA, Aghajanian C, Offit K, Barakat RR, Spriggs DR, Kauff ND.
    • Cancer. 2012 Aug 1;118(15):3703-9. doi: 10.1002/cncr.26655. Epub 2011 Dec 2.

    Press: Does BRCA2+ Confer a Survival Advantage in Ovarian Cancer? (Medscape)

    • Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma.
    • Hyman DM, Long KC, Tanner EJ, Grisham RN, Arnold AG, Bhatia J, Phillips MF, Spriggs DR, Soslow RA, Kauff ND, Levine DA.
    • Gynecol Oncol. 2012 Aug;126(2):224-8. doi: 10.1016/j.ygyno.2012.05.001. Epub 2012 May 8.
    • BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.
    • Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, Dobrovic A, Birrer MJ, Webb PM, Stewart C, Friedlander M, Fox S, Bowtell D, Mitchell G.
    • J Clin Oncol. 2012 Jul 20;30(21):2654-63. doi: 10.1200/JCO.2011.39.8545. Epub 2012 Jun 18.

    Press: Routine BRCA Mutation Testing Urged in Ovarian Cancer. (Medscape/Reuters Health)

    • Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms.
    • Schulz E, Valentin A, Ulz P, Beham-Schmid C, Lind K, Rupp V, Lackner H, Wölfler A, Zebisch A, Olipitz W, Geigl J, Berghold A, Speicher MR, Sill H.
    • J Med Genet. 2012 Jul;49(7):422-8. doi: 10.1136/jmedgenet-2011-100674. Epub 2012 May 31.
    • BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
    • Dann RB, DeLoia JA, Timms KM, Zorn KK, Potter J, Flake DD 2nd, Lanchbury JS, Krivak TC.
    • Gynecol Oncol. 2012 Jun;125(3):677-82. doi: 10.1016/j.ygyno.2012.03.006. Epub 2012 Mar 8.
    • [Clinical features and disease course in patients with BRCA1-dependent ovarian cancer].
    • Blecharz P, Szatkowski W, Bodzek M, Łuczyńska E.
    • Ginekol Pol. 2012 May;83(5):353-6.
    • [Article in Polish]
    • Clinicopathologic characteristics and survival in BRCA1- and BRCA2-related adnexal cancer: are they different?
    • Reitsma W, de Bock GH, Oosterwijk JC, ten Hoor KA, Hollema H, Mourits MJ.
    • Int J Gynecol Cancer. 2012 May;22(4):579-85. doi: 10.1097/IGC.0b013e31823d1b5c.
    • BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma.
    • McAlpine JN, Porter H, Köbel M, Nelson BH, Prentice LM, Kalloger SE, Senz J, Milne K, Ding J, Shah SP, Huntsman DG, Gilks CB.
    • Mod Pathol. 2012 May;25(5):740-50. doi: 10.1038/modpathol.2011.211. Epub 2012 Jan 27.
    • Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: A Gynecologic Oncology Group study.
    • Tian C, Ambrosone CB, Darcy KM, Krivak TC, Armstrong DK, Bookman MA, Davis W, Zhao H, Moysich K, Gallion H, Deloia JA.
    • Gynecol Oncol. 2012 Mar;124(3):575-81. doi: 10.1016/j.ygyno.2011.11.022. Epub 2011 Nov 21.
    • Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project.
    • Gilbert L, Basso O, Sampalis J, Karp I, Martins C, Feng J, Piedimonte S, Quintal L, Ramanakumar AV, Takefman J, Grigorie MS, Artho G, Krishnamurthy S; for the DOvE Study Group.
    • Lancet Oncol. 2012 Mar;13(3):285-91. doi: 10.1016/S1470-2045(11)70333-3. Epub 2012 Jan 17.
    • Online tool to guide decisions for BRCA1/2 mutation carriers.
    • Kurian AW, Munoz DF, Rust P, Schackmann EA, Smith M, Clarke L, Mills MA, Plevritis SK.
    • J Clin Oncol. 2012 Feb 10;30(5):497-506. doi: 10.1200/JCO.2011.38.6060. Epub 2012 Jan 9.

    Comments from NSGC Discussion Forum Cancer SIG

    Subject: An Online BRCA Positive Decision Guidance Tool.

    Comment:

    Are we ready for online tools in decision making for BRCA1/2 mutation carriers?

    Press: Are We Ready for Online Tools in Decision Making for BRCA1/2 Mutation Carriers? (Journal of Clinical Oncology)

    Press: Online tool helps those with BRCA mutations understand options. (Medical Xpress)

    • Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer.
    • Fleming ND, Agadjanian H, Nassanian H, Miller CW, Orsulic S, Karlan BY, Walsh CS.
    • Cancer. 2012 Feb 1;118(3):689-97. doi: 10.1002/cncr.26329. Epub 2011 Jul 12.
    • BRCA1 and BRCA2 mutations in ovarian cancer.
    • Buerkle B, Tempfer C.
    • JAMA. 2012 Jan 25;307(4):359; author reply 360-1. doi: 10.1001/jama.2012.8.
    • Comment, Letter

    Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.

    • Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.
    • Bolton KL, Chenevix-Trench G, Goh C, Sadetzki S, Ramus SJ, Karlan BY, Lambrechts D, Despierre E, Barrowdale D, McGuffog L, Healey S, Easton DF, Sinilnikova O, Benítez J, García MJ, Neuhausen S, Gail MH, Hartge P, Peock S, Frost D, Evans DG, Eeles R, Godwin AK, Daly MB, Kwong A, Ma ES, Lázaro C, Blanco I, Montagna M, D'Andrea E, Nicoletto MO, Johnatty SE, Kjær SK, Jensen A, Høgdall E, Goode EL, Fridley BL, Loud JT, Greene MH, Mai PL, Chetrit A, Lubin F, Hirsh-Yechezkel G, Glendon G, Andrulis IL, Toland AE, Senter L, Gore ME, Gourley C, Michie CO, Song H, Tyrer J, Whittemore AS, McGuire V, Sieh W, Kristoffersson U, Olsson H, Borg Å, Levine DA, Steele L, Beattie MS, Chan S, Nussbaum RL, Moysich KB, Gross J, Cass I, Walsh C, Li AJ, Leuchter R, Gordon O, Garcia-Closas M, Gayther SA, Chanock SJ, Antoniou AC, Pharoah PD; EMBRACE; kConFab Investigators; Cancer Genome Atlas Research Network.
    • JAMA. 2012 Jan 25;307(4):382-90. doi: 10.1001/jama.2012.20.

    Comment, Editorial:

    Unwrapping the implications of BRCA1 and BRCA2 mutations in ovarian cancer.

    Comment:

    [Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer].

    Press: Women With Certain Type of Ovarian Cancer and BRCA Gene Mutation Have Improved Survival at 5 Years. (ScienceDaily)

    Press: Survival Improved in Ovarian Cancer With BRCA Mutation. (Medscape)

    Press: Ovarian cancer survival higher in BRCA mutation carriers. (PHG Foundation)

    • BRCAness profile of sporadic ovarian cancer predicts disease recurrence.
    • Wysham WZ, Mhawech-Fauceglia P, Li H, Hays L, Syriac S, Skrepnik T, Wright J, Pande N, Hoatlin M, Pejovic T.
    • PLoS One. 2012;7(1):e30042. doi: 10.1371/journal.pone.0030042. Epub 2012 Jan 11.
    • Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival.
    • Liu J, Cristea MC, Frankel P, Neuhausen SL, Steele L, Engelstaedter V, Matulonis U, Sand S, Tung N, Garber JE, Weitzel JN.
    • Cancer Genet. 2012 Jan-Feb;205(1-2):34-41. doi: 10.1016/j.cancergen.2012.01.008.
    • Therapy-related myeloid neoplasms in epithelial ovarian cancer patients carrying BRCA1 mutation: report of two cases.
    • Melichar B, Laco J, Fridrichová P, Simkovič M, Papajík T, Foretová L.
    • Acta Oncol. 2012 Jan;51(1):136-8. Epub 2011 Aug 22.